Atrial fibrillation explained

Atrial fibrillation
Field:Cardiology
Symptoms:None, heart palpitations, fainting, dizziness, decreased level or total loss of consciousness, shortness of breath, chest pain
Complications:Heart failure, dementia, stroke
Onset:> age 50
Synonyms:Auricular fibrillation[1]
Risks:High blood pressure, valvular heart disease, coronary artery disease, cardiomyopathy, congenital heart disease, COPD, obesity, smoking, sleep apnea
Diagnosis:Feeling the pulse, electrocardiogram
Differential:Irregular heartbeat[2]
Treatment:Lifestyle modifications, rate control, rhythm control, anticoagulation
Frequency:3.5% (developed world), 1.5% (developing world)
Deaths:315,000 with atrial flutter (2019)[3]

Atrial fibrillation (AF, AFib or A-fib) is an abnormal heart rhythm (arrhythmia) characterized by rapid and irregular beating of the atrial chambers of the heart.[4] It often begins as short periods of abnormal beating, which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF.[5]

Episodes can be asymptomatic. Symptomatic episodes may involve heart palpitations, fainting, lightheadedness, loss of consciousness, shortness of breath, or chest pain.[6] Atrial fibrillation is associated with an increased risk of heart failure, dementia, and stroke. It is a type of supraventricular tachycardia.[7]

Atrial fibrillation frequently results from bursts of tachycardia that originate in muscle bundles extending from the atrium to the pulmonary veins.[8] Pulmonary vein isolation by transcatheter ablation can restore sinus rhythm. The ganglionated plexi (autonomic ganglia of the heart atrium and ventricles) can also be a source of atrial fibrillation, and is sometimes also ablated for that reason.[9] Not only the pulmonary vein, but the left atrial appendage can be a source of atrial fibrillation and is also ablated for that reason.[10]

As atrial fibrillation becomes more persistent, the junction between the pulmonary veins and the left atrium becomes less of an initiator and the left atrium becomes an independent source of arrhythmias.[11]

High blood pressure and valvular heart disease are the most common modifiable risk factors for AF.[12] Other heart-related risk factors include heart failure, coronary artery disease, cardiomyopathy, and congenital heart disease.[13] In low- and middle-income countries, valvular heart disease is often attributable to rheumatic fever. Lung-related risk factors include COPD, obesity, and sleep apnea. Cortisol and other stress biomarkers (including vasopressin, chromogranin A, and heat shock proteins), as well as emotional stress, may play a role in the pathogenesis of atrial fibrillation.[14]

Other risk factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis.[15] However, about half of cases are not associated with any of these aforementioned risks. Moreover, thyrotoxicosis seems to be an especially rare risk factor.[16] Healthcare professionals might suspect AF after feeling the pulse and confirm the diagnosis by interpreting an electrocardiogram (ECG). A typical ECG in AF shows irregularly spaced QRS complexes without P waves.[17]

Healthy lifestyle changes, such as weight loss in people with obesity, increased physical activity, and drinking less alcohol, can lower the risk for AF and reduce its burden if it occurs.[18] AF is often treated with medications to slow the heart rate to a near-normal range (known as rate control) or to convert the rhythm to normal sinus rhythm (known as rhythm control).[13] Electrical cardioversion can convert AF to normal heart rhythm and is often necessary for emergency use if the person is unstable.[19] Ablation may prevent recurrence in some people.[20] For those at low risk of stroke, AF does not necessarily require blood-thinning though some healthcare providers may prescribe aspirin or an anti-clotting medication. Most people with AF are at higher risk of stroke.[21] For those at more than low risk, experts generally recommend an anti-clotting medication. Anti-clotting medications include warfarin and direct oral anticoagulants.[22] While these medications reduce stroke risk, they increase rates of major bleeding.[23]

Atrial fibrillation is the most common serious abnormal heart rhythm and, as of 2020, affects more than 33 million people worldwide.[24] [18] As of 2014, it affected about 2 to 3% of the population of Europe and North America.[25] This was an increase from 0.4 to 1% of the population around 2005.[26] In the developing world, about 0.6% of males and 0.4% of females are affected.[25] The percentage of people with AF increases with age with 0.1% under 50 years old, 4% between 60 and 70 years old, and 14% over 80 years old being affected.[25] A-fib and atrial flutter resulted in 193,300 deaths in 2015, up from 29,000 in 1990.[27] [28] The first known report of an irregular pulse was by Jean-Baptiste de Sénac in 1749.[24] Thomas Lewis was the first doctor to document this by ECG in 1909.[24]

Signs and symptoms

AF is usually accompanied by symptoms related to a rapid heart rate. Rapid and irregular heart rates may be perceived as the sensation of the heart beating too fast, irregularly, or skipping beats (palpitations) or exercise intolerance and occasionally may produce anginal chest pain (if the high heart rate causes the heart's demand for oxygen to increase beyond the supply of available oxygen). Other possible symptoms include congestive heart failure symptoms such as fatigue, shortness of breath, or swelling. Loss of consciousness can also occur on atrial fibrillations due to lack of oxygen and blood to the brain. The abnormal heart rhythm (arrhythmia) is sometimes only identified with the onset of a stroke or a transient ischemic attack (TIA). It is not uncommon for a person to first become aware of AF from a routine physical examination or electrocardiogram, as it often does not cause symptoms.[26]

Since most cases of AF are secondary to other medical problems, the presence of chest pain or angina, signs and symptoms of hyperthyroidism (an overactive thyroid gland) such as weight loss and diarrhea, and symptoms suggestive of lung disease can indicate an underlying cause. A history of stroke or TIA, as well as high blood pressure, diabetes, heart failure, or rheumatic fever, may indicate whether someone with AF is at a higher risk of complications.[26]

Rapid heart rate

Presentation is similar to other forms of rapid heart rate and may be asymptomatic. Palpitations and chest discomfort are common complaints. The rapid uncoordinated heart rate may result in reduced output of blood pumped by the heart (cardiac output), resulting in inadequate blood flow, and therefore oxygen delivery to the rest of the body. Common symptoms of uncontrolled atrial fibrillation may include shortness of breath, shortness of breath when lying flat, dizziness, and sudden onset of shortness of breath during the night. This may progress to swelling of the lower extremities, a manifestation of congestive heart failure. Due to inadequate cardiac output, individuals with AF may also complain of lightheadedness.[29]

AF can cause respiratory distress due to congestion in the lungs. By definition, the heart rate will be greater than 100 beats per minute. Blood pressure may be variable, and often difficult to measure as the beat-by-beat variability causes problems for most digital (oscillometric) non-invasive blood pressure monitors. For this reason, when determining the heart rate in AF, direct cardiac auscultation is recommended. Low blood pressure is most concerning, and a sign that immediate treatment is required. Many of the symptoms associated with uncontrolled atrial fibrillation are a manifestation of congestive heart failure due to the reduced cardiac output. The affected person's respiratory rate often increases in the presence of respiratory distress. Pulse oximetry may confirm the presence of too little oxygen reaching the body's tissues, related to any precipitating factors such as pneumonia. Examination of the jugular veins may reveal elevated pressure (jugular venous distention). Examination of the lungs may reveal crackles, which are suggestive of pulmonary edema. Examination of the heart will reveal a rapid irregular rhythm.

Causes

AF is linked to several forms of cardiovascular disease but may occur in otherwise normal hearts. Cardiovascular factors known to be associated with the development of AF include high blood pressure,[30] coronary artery disease, mitral valve stenosis (e.g., due to rheumatic heart disease or mitral valve prolapse), mitral regurgitation, left atrial enlargement, hypertrophic cardiomyopathy (HCM), pericarditis, congenital heart disease, and previous heart surgery.[31] Congenital heart disease is a strong risk factor for developing atrial fibrillation—a 20-year-old adult with congenital heart disease has a comparable lifetime risk of developing atrial fibrillation when compared to a 55-year-old adult with no history of congenital heart disease.[31] People with congenital heart disease tend to develop atrial fibrillation at a younger age, that is more likely to be of right atrial origin (atypical) than of left origin, and have a greater risk of progressing to permanent atrial fibrillation.[32]

Additionally, lung diseases (such as pneumonia, lung cancer, pulmonary embolism, and sarcoidosis) may play a role in certain people. Sepsis also increases the risk of developing new-onset atrial fibrillation.[33] [34] Disorders of breathing during sleep, such as obstructive sleep apnea (OSA), are also associated with AF.[35] [36] OSA, specifically, was found to be a very strong predictor of atrial fibrillation. Patients with OSA were shown to have an increased incidence of atrial fibrillation and a study done by Gami et al. demonstrated that increased nocturnal oxygen desaturation from OSA severity was correlated with higher incidences of atrial fibrillation.[37] Obesity is a risk factor for AF.[38] Hyperthyroidism and subclinical hyperthyroidism are associated with AF development.[39]

Caffeine consumption does not appear to be associated with AF;[18] [40] excessive alcohol consumption ("binge drinking" or "holiday heart syndrome") is linked to AF.[41] Low-to-moderate alcohol consumption also appears to be associated with an increased risk of developing atrial fibrillation, although the increase in risk associated with drinking less than two drinks daily appears to be small.[41] Tobacco smoking and secondhand tobacco smoke exposure are associated with an increased risk of developing atrial fibrillation.[42] [43] Long-term endurance exercise that far exceeds the recommended amount of exercise (e.g., long-distance cycling or marathon running) appears to be associated with a modest increase in the risk of atrial fibrillation in middle-aged and elderly people.[44] [45]

Major stress biomarkers (including cortisol and heat shock proteins) indicate that stress plays a significant role in causing atrial fibrillation.[14] There is some evidence that night shift working may be linked to a diagnosis of AF.[46]

Atrial fibrillation is associated with elevated levels of inflammatory markers and clotting factors.[47] Mendelian randomization indicates a causal relationship of inflammation leading to atrial fibrillation.[48]

Genetics

A family history of AF may increase the risk of AF. A study of more than 2,200 people found an increased risk factor for AF of 1.85 for those that had at least one parent with AF.[49] [50] [51] Various genetic mutations may be responsible.[52] [53]

Four types of genetic disorder are associated with atrial fibrillation:[54]

Family history in a first degree relative is associated with a 40% increase in risk of AF. This finding led to the mapping of different loci such as 10q22-24, 6q14-16 and 11p15-5.3 and discover mutations associated with the loci. Fifteen mutations of gain and loss of function have been found in the genes of K+ channels, including mutations in KCNE1-5, KCNH2, KCNJ5 or ABCC9 among others. Six variations in genes of Na+ channels that include SCN1-4B, SCN5A and SCN10A have also been found. All of these mutations affect the processes of polarization-depolarization of the myocardium, cellular hyper-excitability, shortening of effective refractory period favoring re-entries.[55] Other mutations in genes, such as GJA5, affect gap junctions, generating a cellular uncoupling that promotes re-entries and a slow conduction velocity.[56] Using genome-wide association study, which screen the entire genome for single nucleotide polymorphism (SNP), three susceptibility loci have been found for AF (4q25, 1q21 and 16q22).[57] In these loci there are SNPs associated with a 30% increase in risk of recurrent atrial tachycardia after ablation. There are also SNPs associated with loss of function of the Pitx2c gene (involved in cellular development of pulmonary valves), responsible for re-entries. There are also SNPs close to ZFHX3 genes involved in the regulation of Ca2+.A GWAS meta-analysis study conducted in 2018 revealed the discovery of 70 new loci associated with AF. Different variants have been identified. They are associated with genes that encode transcription factors, such as TBX3 and TBX5, NKX2-5 or PITX2, involved in the regulation of cardiac conduction, modulation of ion channels and in cardiac development. Have been also identified new genes involved in tachycardia (CASQ2) or associated with an alteration in cardiomyocyte communication (PKP2).[58] Rare mutations in the cardiomyopathy gene TTN may also increase the risk of AF, even in individuals without signs of heart failure.[59] [60] Small genetic deletions on the X chromosome around the STS (steroid sulfatase) gene are associated with increased rates of AF in males;[61] common genetic risk variants around STS appear to be associated with AF[62]

Sedentary lifestyle

A sedentary lifestyle increases the risk factors associated with AF, such as obesity, hypertension, or diabetes mellitus. This favors remodeling processes of the atrium due to inflammation or alterations in the depolarization of cardiomyocytes by elevation of sympathetic nervous system activity.[63] A sedentary lifestyle is associated with an increased risk of AF compared to physical activity. In both men and women, the practice of moderate exercise reduces the risk of AF progressively;[64] intense sports may increase the risk of developing AF, as seen in athletes.[65] It is due to a remodeling of cardiac tissue,[66] and an increase in vagal tone, which shortens the effective refractory period (ERP) favoring re-entries from the pulmonary veins.

Tobacco

The rate of AF in smokers is 1.4 times higher than in non-smokers. However, snus consumption, which delivers nicotine at a dose equivalent to that of cigarettes and is debated as a harm-reduction product, is not correlated with AF.[67]

Alcohol

Acute alcohol consumption can directly trigger an episode of atrial fibrillation.[41] Regular alcohol consumption also increases the risk of atrial fibrillation in several ways.[41] The long-term use of alcohol alters the physical structure and electrical properties of the atria.[41] Alcohol consumption does this by repeatedly stimulating the sympathetic nervous system, increasing inflammation in the atria, raising blood pressure, lowering the levels of potassium and magnesium in the blood, worsening obstructive sleep apnea, and by promoting harmful structural changes (remodeling) in the atria and ventricles of the heart.[41] This remodeling leads to abnormally increased pressure in the left atrium, inappropriately dilates it, and increases scarring (fibrosis) in the left atrium.[41] The aforementioned structural changes increase the risk of developing atrial fibrillation when paired with the harmful changes in how the left atrium conducts electricity.[41]

High blood pressure (hypertension)

In patients with hypertension prevalence rates reportedly range from 49% to 90%.[68] According to the CHARGE Consortium, both systolic and diastolic blood pressure are predictors of the risk of AF. Systolic blood pressure values close to normal limit the increase in the risk associated with AF. Diastolic dysfunction is also associated with AF, which increases left atrial pressure, left atrial volume, size, and left ventricular hypertrophy, characteristic of chronic hypertension. All atrial remodeling is related to heterogeneous conduction and the formation of re-entrant electric conduction from the pulmonary veins.[69]

Other diseases

There is a relationship between risk factors such as obesity and hypertension, with the appearance of diseases such as diabetes mellitus and sleep apnea-hypopnea syndrome, specifically, obstructive sleep apnea (OSA). These diseases are associated with an increased risk of AF due to their remodeling effects on the left atrium.

Medications

Several medications are associated with an increased risk of developing atrial fibrillation.[70] Few studies have examined this phenomenon, and the exact incidence of medication-induced atrial fibrillation is unknown.[70] Medications that are commonly associated with an increased risk of developing atrial fibrillation include dobutamine and the chemotherapy agent cisplatin.[70] Agents associated with a moderately increased risk include nonsteroidal anti-inflammatory drugs (e.g., ibuprofen), bisphosphonates, and other chemotherapeutic agents such as melphalan, interleukin 2, and anthracyclines.[70] Other medications that rarely increase the risk of developing atrial fibrillation include adenosine, aminophylline, corticosteroids, ivabradine, ondansetron, and antipsychotics.[70] This form of atrial fibrillation occurs in people of all ages but is most common in the elderly, in those with other atrial fibrillation risk factors, and after heart surgery.[70]

Pathophysiology

The normal electrical conduction system of the heart allows electrical impulses generated by the heart's own pacemaker (the sinoatrial node) to spread to and stimulate the muscular layer of the heart (myocardium) in both the atria and the ventricles. When the myocardium is stimulated it contracts, and if this occurs in an orderly manner allows blood to be pumped to the body. In AF, the normal regular electrical impulses generated by the sinoatrial node are overwhelmed by disorganized electrical waves, usually originating from the roots of the pulmonary veins. These disorganized waves conduct intermittently through the atrioventricular node, leading to irregular activation of the ventricles that generate the heartbeat.

Pathology

The primary pathologic change seen in atrial fibrillation is the progressive fibrosis of the atria. This fibrosis is due primarily to atrial dilation; however, genetic causes and inflammation may be factors in some individuals. Dilation of the atria can be due to almost any structural abnormality of the heart that can cause a rise in the pressure within the heart. This includes valvular heart disease (such as mitral stenosis, mitral regurgitation, and tricuspid regurgitation), hypertension, and congestive heart failure. Any inflammatory state that affects the heart can cause fibrosis of the atria. This is typically due to sarcoidosis but may also be due to autoimmune disorders that create autoantibodies against myosin heavy chains. Mutation of the lamin AC gene is also associated with fibrosis of the atria that can lead to atrial fibrillation.

Once dilation of the atria has occurred, this begins a chain of events that leads to the activation of the renin–angiotensin–aldosterone system (RAAS) and subsequent increase in the matrix metalloproteinases and disintegrin, which leads to atrial remodeling and fibrosis, with loss of atrial muscle mass. This process occurs gradually, and experimental studies have revealed patchy atrial fibrosis may precede the occurrence of atrial fibrillation and may progress with prolonged durations of atrial fibrillation.

Fibrosis is not limited to the muscle mass of the atria and may occur in the sinus node (SA node) and atrioventricular node (AV node), correlating with sick sinus syndrome. Prolonged episodes of atrial fibrillation have been shown to correlate with prolongation of the sinus node recovery time;[26] this suggests that dysfunction of the SA node is progressive with prolonged episodes of atrial fibrillation.

Along with fibrosis, alterations in the atria that predispose to atrial fibrillation affect their electrical properties, as well as their responsiveness to the autonomic nervous system. The atrial remodeling that includes the pathologic changes described above has been referred to as atrial myopathy.[71]

Electrophysiology

There are multiple theories about the cause of atrial fibrillation. An important theory is that the regular impulses produced by the sinus node for a normal heartbeat are overwhelmed by rapid electrical discharges produced in the atria and adjacent parts of the pulmonary veins. Non-pulmonary vein sources of triggers for atrial fibrillation have been identified in 10% to 33% of patients. These triggers include the coronary sinus, the posterior wall of the left atrium, and the left atrial appendage.

Sources of these disturbances are either automatic foci, often localized at one of the pulmonary veins, or a small number of localized sources in the form of either a re-entrant leading circle or electrical spiral waves (rotors); these localized sources may be in the left atrium near the pulmonary veins or in a variety of other locations through both the left or right atrium. Three fundamental components favor the establishment of a leading circle or a rotor: slow conduction velocity of the cardiac action potential, a short refractory period, and a small wavelength. Meanwhile, the wavelength is the product of velocity and refractory period. If the action potential has fast conduction, with a long refractory period and/or conduction pathway shorter than the wavelength, an AF focus would not be established. In multiple wavelet theory, a wavefront will break into smaller daughter wavelets when encountering an obstacle, through a process called vortex shedding. But, under the proper conditions, such wavelets can reform and spin around a center, forming an AF focus.[72]

In a heart with AF, the increased calcium release from the sarcoplasmic reticulum and increased calcium sensitivity can lead to an accumulation of intracellular calcium and causes downregulation of L-type calcium channels. This reduces the duration of action potential and the refractory period, thus favoring the conduction of re-entrant waves. Increased expression of inward-rectifier potassium ion channels can cause a reduced atrial refractory period and wavelength. The abnormal distribution of gap junction proteins such as GJA1 (also known as Connexin 43), and GJA5 (Connexin 40) causes non-uniformity of electrical conduction, thus causing the arrhythmia.[73]

AF can be distinguished from atrial flutter (AFL), which appears as an organized electrical circuit usually in the right atrium. AFL produces characteristic saw-toothed F-waves of constant amplitude and frequency on an ECG, whereas AF does not. In AFL, the discharges circulate rapidly at a rate of 300 beats per minute (bpm) around the atrium. In AF, there is no such regularity, except at the sources where the local activation rate can exceed 500 bpm. Although AF and atrial flutter are distinct arrhythmias, atrial flutter may degenerate into AF, and an individual may experience both arrhythmias at different times.

Although the electrical impulses of AF occur at a high rate, most of them do not result in a heartbeat. A heartbeat results when an electrical impulse from the atria passes through the atrioventricular (AV) node to the ventricles and causes them to contract. During AF, if all of the impulses from the atria passed through the AV node, there would be severe ventricular tachycardia, resulting in a severe reduction of cardiac output. This dangerous situation is prevented by the AV node since its limited conduction velocity reduces the rate at which impulses reach the ventricles during AF.[74]

Diagnosis

The evaluation of atrial fibrillation involves a determination of the cause of the arrhythmia, and classification of the arrhythmia. Diagnostic investigation of AF typically includes a complete history and physical examination, ECG, transthoracic echocardiogram, complete blood count, serum thyroid stimulating hormone level[29] and may include a functionality of some smartwatches.[75] Von Willebrand factor is a marker of endothelial dysfunction, and is consistently elevated in atrial fibrillation, associated with adverse outcomes.[76]

Screening

Numerous guidelines recommend opportunistic screening for atrial fibrillation in those 65 years and older. These organizations include the: European Society of Cardiology,[77] National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand[78] European Heart Rhythm Society,[79] [80] AF-SCREEN International Collaboration,[81] Royal College of Physicians of Edinburgh[82] European Primary Care Cardiovascular Society,[83] and Irish Health Information and Quality Authority.[84]

Single timepoint screening detects undiagnosed AF, which is often asymptomatic, in approximately 1.4% of people in this age group.[85] A Scottish inquiry into atrial fibrillation estimated that as many as one-third of people with AF are undiagnosed. Despite this, in 2018, the United States Preventive Services Task Force found insufficient evidence to determine the usefulness of routine screening.[86] Given the importance of having a pathway to treatment, general practice is potentially an ideal setting to conduct AF screening. General practice was identified as a 'preferred' setting for AF screening by the AF-SCREEN international collaboration report due to the availability of nursing support and the natural pathway to treatment.[81] Screening in primary care has been trialled in a number of countries. These include: a recent Canadian study conducted in 184 general practices;[87] a screening program conducted alongside influenza vaccinations in 10 Dutch practices;[88] and several Australian studies showed that opportunistic screening in primary care by GPs and nurses using eHealth tools was feasible.[89] [90] [91] [92]

Minimal evaluation

In general, the minimal evaluation of atrial fibrillation should be performed in all individuals with AF. The goal of this evaluation is to determine the general treatment regimen for the individual. If the results of the general evaluation warrant it, further studies may then be performed.

History and physical examination

The history of the individual's atrial fibrillation episodes is probably the most important part of the evaluation. Distinctions should be made between those who are entirely asymptomatic when they are in AF (in which case the AF is found as an incidental finding on an ECG or physical examination) and those who have gross and obvious symptoms due to AF and can pinpoint whenever they go into AF or revert to sinus rhythm.

Routine bloodwork

While many cases of AF have no definite cause, it may be the result of various other problems. Hence, kidney function and electrolytes are routinely determined, as well as thyroid-stimulating hormone (commonly suppressed in hyperthyroidism and of relevance if amiodarone is administered for treatment) and a blood count.[26]

In acute-onset AF associated with chest pain, cardiac troponins, or other markers of damage to the heart muscle may be ordered. Coagulation studies (INR/aPTT) are usually performed, as anticoagulant medication may be commenced.[26]

Electrocardiogram

Atrial fibrillation is diagnosed on an electrocardiogram (ECG), an investigation performed routinely whenever an irregular heartbeat is suspected. Characteristic findings are the absence of P waves, with disorganized electrical activity in their place, and irregular R–R intervals due to irregular conduction of impulses to the ventricles.[26] At very fast heart rates, atrial fibrillation may look more regular, which may make it more difficult to separate from other supraventricular tachycardias or ventricular tachycardia.[93]

QRS complexes should be narrow, signifying that they are initiated by normal conduction of atrial electrical activity through the intraventricular conduction system. Wide QRS complexes are worrisome for ventricular tachycardia, although, in cases where there is a disease of the conduction system, wide complexes may be present in A-fib with a rapid ventricular response.

If paroxysmal AF is suspected, but an ECG during an office visit shows only a regular rhythm, AF episodes may be detected and documented with the use of ambulatory Holter monitoring (e.g., for a day). If the episodes are too infrequent to be detected by Holter monitoring with reasonable probability, then the person can be monitored for longer periods (e.g., a month) with an ambulatory event monitor.[26]

Echocardiography

In general, a non-invasive transthoracic echocardiogram (TTE) is performed in newly diagnosed AF, as well as if there is a major change in the person's clinical state. This ultrasound-based scan of the heart may help identify valvular heart disease (which may greatly increase the risk of stroke and alter recommendations for the appropriate type of anticoagulation), left and right atrial size (which predicts the likelihood that AF may become permanent), left ventricular size and function, peak right ventricular pressure (pulmonary hypertension), presence of left atrial thrombus (low sensitivity), presence of left ventricular hypertrophy and pericardial disease.[26]

Significant enlargement of both the left and right atria is associated with long-standing atrial fibrillation and, if noted at the initial presentation of atrial fibrillation, suggests that the atrial fibrillation is likely to be of a longer duration than the individual's symptoms.

Extended evaluation

In general, an extended evaluation is not necessary for most individuals with atrial fibrillation and is performed only if abnormalities are noted in the limited evaluation, if a reversible cause of the atrial fibrillation is suggested, or if further evaluation may change the treatment course.

Chest X-ray

In general, a chest X-ray is performed only if a pulmonary cause of atrial fibrillation is suggested, or if other cardiac conditions are suspected (in particular congestive heart failure). This may reveal an underlying problem in the lungs or the blood vessels in the chest.[26] In particular, if underlying pneumonia is suggested, then treatment of the pneumonia may cause the atrial fibrillation to terminate on its own.

Transesophageal echocardiogram

A regular echocardiogram (transthoracic echo/TTE) has a low sensitivity for identifying blood clots in the heart. If this is suspected (e.g., when planning urgent electrical cardioversion), a transesophageal echocardiogram/TEE (or TOE where British spelling is used) is preferred.[26]

The TEE has much better visualization of the left atrial appendage than transthoracic echocardiography.[94] This structure, located in the left atrium, is the place where a blood clot forms in more than 90% of cases in non-valvular (or non-rheumatic) atrial fibrillation.[95] TEE has a high sensitivity for locating thrombi in this area and can also detect sluggish blood flow in this area that is suggestive of blood clot formation.[94]

If a blood clot is seen on TEE, then cardioversion is contraindicated due to the risk of stroke, and anticoagulation is recommended.

Ambulatory Holter monitoring

A Holter monitor is a wearable ambulatory heart monitor that continuously monitors the heart rate and heart rhythm for a short duration, typically 24 hours. In individuals with symptoms of significant shortness of breath with exertion or palpitations regularly, a Holter monitor may be of benefit to determine whether rapid heart rates (or unusually slow heart rates) during atrial fibrillation are the cause of the symptoms.

Exercise stress testing

Some individuals with atrial fibrillation do well with normal activity but develop shortness of breath with exertion. It may be unclear whether the shortness of breath is due to a blunted heart rate response to exertion caused by excessive atrioventricular node-blocking agents, a very rapid heart rate during exertion, or other underlying conditions such as chronic lung disease or coronary ischemia. An exercise stress test will evaluate the individual's heart rate response to exertion and determine whether the AV node blocking agents are contributing to the symptoms.

Classification

Classification system
AF categoryDefining characteristics
  First detected  only one diagnosed episode
  Paroxysmal  recurrent episodes that stop on their own in less than seven days
  Persistent  recurrent episodes that last more than seven days
  Longstanding Persistent  recurrent episodes that last more than twelve months
  Permanent  AF that has been accepted, and for which a solely rate control strategy has been decided upon.

The American College of Cardiology (ACC), American Heart Association (AHA), and the European Society of Cardiology (ESC) recommend in their guidelines the following classification system based on simplicity and clinical relevance.

All people with AF are initially in the category called first detected AF. These people may or may not have had previous undetected episodes. If a first detected episode stops on its own in less than seven days and then another episode begins, later on, the category changes to paroxysmal AF. Although people in this category have episodes lasting up to seven days, in most cases of paroxysmal AF, the episodes will stop in less than 24 hours. If the episode lasts for more than seven days, it is unlikely to stop on its own and is then known as persistent AF. In this case, cardioversion can be attempted to restore a normal rhythm. If an episode continues for a year or more, the rhythm is then known as longstanding persistent AF. If a decision is made by the person and their medical team to accept persistent AF and not attempt restoration of a normal sinus rhythm but instead manage the AF by simply controlling the person's ventricular rate then the rhythm is referred to as permanent AF. As a further subtype, AF that is detected only by an implanted or wearable cardiac monitor is known as subclinical AF.

Episodes that last less than 30 seconds are not considered in this classification system. Also, this system does not apply to cases where the AF is a secondary condition that occurs in the setting of a primary condition that may be the cause of the AF.

About half of people with AF have permanent AF, while a quarter have paroxysmal AF, and a quarter have persistent AF.[25]

In addition to the above AF categories, which are mainly defined by episode timing and termination, the ACC/AHA/ESC guidelines describe additional AF categories in terms of other characteristics of the person. Valvular AF refers to AF attributable to moderate to severe mitral valve stenosis or atrial fibrillation in the presence of a mechanical artificial heart valve.[96] This distinction may be useful as it has implications on appropriate treatment, including differing recommendations for anticoagulation, but the most recent guidelines discourage use of this term as it may be confusing. Other historically used definitions include lone AF – AF occurring in those aged under 60 in the absence of other cardiovascular or respiratory diseases. This description is also discouraged as it is recognised that AF always has an underlying cause. Secondary AF refers to AF that occurs in the setting of another condition that have caused the AF, such as acute myocardial infarction, cardiac surgery, pericarditis, myocarditis, hyperthyroidism, pulmonary embolism, pneumonia, or another acute pulmonary disease.

Prevention

Prevention of atrial fibrillation focuses primarily on preventing or controlling its risk factors. Many of its risk factors, such as obesity, smoking, lack of physical activity, and excessive alcohol consumption, are modifiable and preventable with lifestyle modification or can be managed by a healthcare professional.

Lifestyle modification

Several healthy lifestyle behaviors are associated with a lower likelihood of developing atrial fibrillation. Accordingly, consensus guidelines recommend abstaining from alcohol and recreational drugs, stopping tobacco use, maintaining a healthy weight, and regularly participating in moderate-intensity physical activities.[70] Consistent moderate-intensity aerobic exercise, defined as achieving 3.0–5.9 METs of intensity, for at least 150 minutes per week may reduce the risk of developing new-onset atrial fibrillation.[18] Few studies have examined the role of specific dietary changes and how it relates to the prevention of atrial fibrillation.[70]

Management

See main article: Management of atrial fibrillation. The main goals of treatment are to prevent circulatory instability and stroke. Rate or rhythm control is used to achieve the former, whereas anticoagulation is used to decrease the risk of the latter.[97] If cardiovascularly unstable due to uncontrolled tachycardia, immediate cardioversion is indicated.[26] Many antiarrhythmics, when used long term, increase the risk of death without any meaningful benefit.[98] An integrated management approach, which includes stroke prevention, symptoms control and management of associated comorbidities has been associated with better outcomes in patients with atrial fibrillation.[99] [100] [101] [102]

This holistic or integrated care approach is summed up as the ABC (Atrial fibrillation Better Care) pathway,[103] as follows:

Lifestyle modification

Regular aerobic exercise improves atrial fibrillation symptoms and AF-related quality of life.[18] The effect of high-intensity interval training on reducing atrial fibrillation burden is unclear.[18] Weight loss of at least 10% is associated with reduced atrial fibrillation burden in people who are overweight or obese.[18]

Comorbidity treatment

For people who have both atrial fibrillation and obstructive sleep apnea, observational studies suggest that continuous positive airway pressure (CPAP) treatment appears to lower the risk of atrial fibrillation recurrence after undergoing ablation.[18] Randomized controlled trials examining the role of obstructive sleep apnea treatment on atrial fibrillation incidence and burden are lacking.[18] Guideline-recommended lifestyle and medical interventions are recommended for people with atrial fibrillation and coexisting conditions such as hyperlipidemia, diabetes mellitus, or hypertension without specific blood sugar or blood pressure targets for people with atrial fibrillation.[18]

Bariatric surgery may reduce the risk of new-onset atrial fibrillation in people with obesity without AF and may reduce the risk of a recurrence of AF after an ablation procedure in people with coexisting obesity and atrial fibrillation.[18] It is important for all people with atrial fibrillation to optimize the control of all coexisting medical conditions that can worsen their atrial fibrillation, such as hyperthyroidism, diabetes, congestive heart failure,[105] high blood pressure,[106] chronic obstructive pulmonary disease,[107] [108] stimulant use (e.g., methamphetamine dependence), and excessive alcohol consumption.[109]

Anticoagulants

Anticoagulation can be used to reduce the risk of stroke from AF. Anticoagulation is recommended in most people other than those at low risk of stroke[110] [111] or those at high risk of bleeding. The risk of falls and consequent bleeding in frail elderly people should not be considered a barrier to initiating or continuing anticoagulation since the risk of fall-related brain bleeding is low and the benefit of stroke prevention often outweighs the risk of bleeding.[112] Similarly, the presence or absence of AF symptoms does not determine whether a person warrants anticoagulation and is not an indicator of stroke risk.[113] Oral anticoagulation is underused in atrial fibrillation, while aspirin is overused in many who should be treated with a direct oral anticoagulant (DOAC) or warfarin.[114] In 2019, DOACs were often recommended over warfarin by the American Heart Association.[115]

The risk of stroke from non-valvular AF can be estimated using the CHA2DS2-VASc score. In the 2019 AHA/ACC/HRS guidelines anticoagulation is recommended in non-valvular AF if there is a score of two or more in men and three or more in women and may be considered if there is a score of one in men or two in women; not using anticoagulation is reasonable if there is a score of zero in men or one in women.[115] Guidelines from the American College of Chest Physicians, Asia-Pacific Heart Rhythm Society, Canadian Cardiovascular Society, European Society of Cardiology, Japanese Circulation Society, Korean Heart Rhythm Society, and the National Institute for Health and Care Excellence recommend the use of novel oral anticoagulants or warfarin with a CHA2DS2-VASc score of one over aspirin and some directly recommend against aspirin.[116] [117] [118] [119] [120] [121] [122] [123] Experts generally advocate for most people with atrial fibrillation with CHA2DS2-VASc scores of one or more receiving anticoagulation though aspirin is sometimes used for people with a score of one (moderate risk for stroke). There is little evidence to support the idea that the use of aspirin significantly reduces the risk of stroke in people with atrial fibrillation.[124] Furthermore, aspirin's major bleeding risk (including bleeding in the brain) is similar to that of warfarin and DOACs despite its inferior efficacy.[114] [125]

Anticoagulation can be achieved through several means including warfarin,[126] heparin, dabigatran, rivaroxaban,[127] edoxaban,[128] and apixaban.[129] Many issues should be considered related to their comparative effectiveness, including the cost of DOACs, risk of stroke, risk of falls, comorbidities (such as chronic liver or kidney disease), the presence of significant mitral stenosis or mechanical heart valves, compliance, and speed of the desired onset of anticoagulation.[130] [96] [131] The optimal approach to anticoagulation in people with AF and who simultaneously have other diseases (e.g., cirrhosis and end-stage kidney disease on dialysis) that predispose a person to both bleeding and clotting complications is unclear.[132] [133]

For those with non-valvular atrial fibrillation, DOACs are at least as effective as warfarin for preventing strokes and blood clots embolizing to the systemic circulation (if not more so) and are generally preferred over warfarin.[96] [134] DOACs carry a lower risk of bleeding in the brain compared to warfarin,[135] although dabigatran is associated with a higher risk of intestinal bleeding.[136] [134] Dual antiplatelet therapy with aspirin and clopidogrel is inferior to warfarin for preventing strokes or systemic embolism and has comparable bleeding risk in people with atrial fibrillation.[110] [137] In those who are also on aspirin, however, DOACs appear to be better than warfarin.[138]

Time in therapeutic range (TTR) and INR variability are commonly used to assess the quality of VKA treatment. Patients who are unable to maintain a therapeutic INR on VKA, as indicated by low TTR and/or high INR variability, are at an increased risk of thromboembolic and bleeding events.[139] In these patients, treatment with a DOAC is recommended.[96] While there are no significant changes in adherence, persistence or clinical outcomes in patients switched from a VKA to a DOAC, an increase in therapy satisfaction has been reported.[140] [141]

DOAC therapy is not recommended for all patients with atrial fibrillation. For instance, warfarin is the recommended anticoagulant for patients with atrial fibrillation who have mechanical heart valves.

Rate versus rhythm control

There are two ways to approach atrial fibrillation using medications: rate control and rhythm control. Both methods have similar outcomes.[142] Rate control lowers the heart rate closer to normal, usually 60 to 100 bpm, without trying to convert to a regular rhythm. Rhythm control tries to restore a normal heart rhythm in a process called cardioversion and maintains the normal rhythm with medications. Studies suggest that rhythm control is more important in the acute setting AF, whereas rate control is more important in the chronic phase.

The risk of stroke appears to be lower with rate control versus attempted rhythm control, at least in those with heart failure.[143] AF is associated with a reduced quality of life, and, while some studies indicate that rhythm control leads to a higher quality of life, some did not find a difference.[144]

Neither rate nor rhythm control is superior in people with heart failure when they are compared in various clinical trials. However, rate control is recommended as the first-line treatment regimen for people with heart failure. On the other hand, rhythm control is only recommended when people experience persistent symptoms despite adequate rate control therapy.[145]

In those with a fast ventricular response, intravenous magnesium significantly increases the chances of achieving successful rate and rhythm control in the urgent setting without major side-effects.[146] A person with poor vital signs, mental status changes, preexcitation, or chest pain often will go to immediate treatment with synchronized DC cardioversion.[26] Otherwise, the decision of rate control versus rhythm control using medications is made. This is based on several criteria that include whether or not symptoms persist with rate control.

Rate control

Rate control to a target heart rate of fewer than 110 beats per minute is recommended in most people. Lower heart rates may be recommended in those with left ventricular hypertrophy or reduced left ventricular function.[147] Rate control is achieved with medications that work by increasing the degree of the block at the level of the AV node, decreasing the number of impulses that conduct into the ventricles. This can be done with:[26] [148]

Patients with chronic AF are recommended to take either beta blockers or calcium channel blockers.[149]

In addition to these agents, amiodarone has some AV node blocking effects (in particular when administered intravenously) and can be used in individuals when other agents are contraindicated or ineffective (particularly due to hypotension).

Cardioversion

Cardioversion is the attempt to switch an irregular heartbeat to a normal heartbeat using electrical or chemical means.[26]

After successful cardioversion, the heart may be stunned, which means that there is a normal rhythm, but the restoration of normal atrial contraction has not yet occurred.[152]

Surgery

Ablation

Catheter ablation (CA) is a procedure performed by an electrophysiologist, a cardiologist who specializes in heart rhythm problems, to restore the heart's normal rhythm by destroying, or electrically isolating, specific parts of the atria. A group of cardiologists led by Dr Haïssaguerre from Bordeaux University Hospital noted in 1998 that the pulmonary veins are an important source of ectopic beats, initiating frequent paroxysms of atrial fibrillation, with these foci responding to treatment with radio-frequency ablation.[153] Most commonly, CA electrically isolates the left atrium from the pulmonary veins, where most of the abnormal electrical activity promoting atrial fibrillation originates. CA is a form of rhythm control that restores normal sinus rhythm and reduces AF-associated symptoms more reliably than antiarrhythmic medications.

Electrophysiologists generally use two forms of catheter ablation—radiofrequency ablation, or cryoablation. In young people with little-to-no structural heart disease where rhythm control is desired and cannot be maintained by medication or cardioversion, radiofrequency catheter ablation or cryoablation may be attempted and may be preferred over several years of medical therapy.[26] [154] Although radiofrequency ablation has become an accepted intervention in selected younger people and may be more effective than medication at improving symptoms and quality of life, there is no evidence that ablation reduces all-cause mortality, stroke, or heart failure.[155] Some evidence indicates CA may be particularly helpful for people with AF who also have heart failure.[156] AF may recur in people who have undergone CA and nearly half of people who undergo it will require a repeat procedure to achieve long-term control of their AF.[155]

In general, CA is more successful at preventing AF recurrence if AF is paroxysmal as opposed to persistent.[157] As CA does not reduce the risk of stroke, many are advised to continue their anticoagulation.[155] Possible complications include common, minor complications such as the formation of a collection of blood at the site where the catheter goes into the vein (access site hematoma), but also more dangerous complications including bleeding around the heart (cardiac tamponade), stroke, damage to the esophagus (atrio-esophageal fistula), or even death.[155] [158] Use of pulsed field ablation as a non-thermal method of inducing electroporation avoids damage to the phrenic nerve, esophagus, and blood vessels, while being at least as effective as thermal ablation methods.[159]

A hybrid convergent procedure has been developed which combines endocardial ablation with epicardial ablation, which can reduce AF recurrence to less than 5% for over one year.[160] The epicardial ablation is performed first, with a minimally invasive surgical approach.[161]

Maze procedure

An alternative to catheter ablation is surgical ablation. The maze procedure, first performed in 1987, is an effective invasive surgical treatment that is designed to create electrical blocks or barriers in the atria of the heart. The idea is to force abnormal electrical signals to move along one, uniform path to the lower chambers of the heart (ventricles), thus restoring the normal heart rhythm.[162] People with AF often undergo cardiac surgery for other underlying reasons and are frequently offered concomitant AF surgery to reduce the frequency of short- and long-term AF. Concomitant AF surgery is more likely to lead to the person being free from atrial fibrillation and off medications long-term after surgery and Cox-Maze IV procedure is the gold standard treatment. There is a slightly increased risk of needing a pacemaker following the procedure.[163] [164] [165] Less invasive modifications of the maze procedure have been developed, designated as minimaze procedures.

Left atrial appendage occlusion

There is growing evidence that left atrial appendage occlusion therapy may reduce the risk of stroke in people with non-valvular AF as much as warfarin.[166] [167] The addition of left atrial appendage isolation to catheter ablation has reduced AF recurrence by 80% in patients with persistent AF.[168]

After surgery

After catheter ablation, people are moved to a cardiac recovery unit, intensive care unit, or cardiovascular intensive care unit where they are not allowed to move for 46 hours. Minimizing movement helps prevent bleeding from the site of the catheter insertion. The length of time people stay in the hospital varies from hours to days. This depends on the problem, the length of the operation, and whether or not general anesthetic was used. Additionally, people should not engage in strenuous physical activityto maintain a low heart rate and low blood pressurefor around six weeks.[169]

AF often occurs after cardiac surgery and is usually self-limiting. It is strongly associated with age, preoperative hypertension, and the number of vessels grafted. Measures should be taken to control hypertension preoperatively to reduce the risk of AF. Also, people with a higher risk of AF, e.g., people with pre-operative hypertension, more than three vessels grafted, or greater than 70 years of age, should be considered for prophylactic treatment. Postoperative pericardial effusion is also suspected to be the cause of atrial fibrillation. Prophylaxis may include prophylactic postoperative rate and rhythm management. Some authors perform posterior pericardiotomy to reduce the incidence of postoperative AF.[170] When AF occurs, management should primarily be rate and rhythm control. However, cardioversion may be used if the patient is hemodynamically unstable, highly symptomatic, or AF persists for six weeks after discharge. In persistent cases, anticoagulation should be used.

Prognosis

Atrial fibrillation can progress from infrequent occurrences to more frequent occurrences, ultimately becoming permanent.[171] Some cases do not progress, especially among patients with a healthy lifestyle.[172]

Many mechanisms contribute to cardiac remodeling leading to a worsening of atrial fibrillation, including fibrosis, fatty infiltration, amyloidosis, and ion channel modifications.[173] Fatty infiltration helps explain why obesity is a risk factor for atrial fibrillation in one fifth of patients.

Atrial fibrillation increases the risk of heart failure by 11 per 1000, kidney problems by 6 per 1000, death by 4 per 1000, stroke by 3 per 1000, and coronary heart disease by 1 per 1000.[174] Women have a worse outcome overall than men.[175] Evidence increasingly suggests that atrial fibrillation is independently associated with a higher risk of developing dementia.[176]

Blood clots

See also: CHA2DS2-VASc score.

Prediction of embolism

Among Danish men aged 50, with no risk factors, the 5-year risk of stroke was 1.1% and with AF alone 2.5%. For women the risks were slightly less, 0.7% and 2.1%. For men aged 70, the 5-year risk of stroke was 4.8% and with AF alone 6.8%. For women aged 70 the risk was again lower than for men, 3.4% with no added risk factor and 8.2% with AF.[177]

Determining the risk of an embolism causing a stroke is important for guiding the use of anticoagulants. The most accurate clinical prediction rules are:[178]

Both the CHADS2 and the CHA2DS2-VASc score predict future stroke risk in people with A-fib with CHA2DS2-VASc score being more accurate. The addition of blood based biomarkers such as NT-proBNP and neurofilament light chain improves risk prediction significantly.[179] Some that had a CHADS2 score of zero had a CHA2DS2-VASc score of three, with a 3.2% annual risk of stroke. Thus, a CHA2DS2-VASc score of zero is considered very low risk.[180]

Mechanism of thrombus formation

In atrial fibrillation, the lack of an organized atrial contraction can result in some stagnant blood in the left atrium (LA) or left atrial appendage (LAA). This lack of movement of blood can lead to thrombus formation (blood clotting). If the clot becomes mobile and is carried away by the blood circulation, it is called an embolus. An embolus proceeds through smaller and smaller arteries until it plugs one of them and prevents blood from flowing through the artery. This process results in end organ damage due to the loss of nutrients, oxygen, and the removal of cellular waste products. Emboli in the brain may result in an ischemic stroke or a transient ischemic attack (TIA).

More than 90% of cases of thrombi associated with non-valvular atrial fibrillation evolve in the left atrial appendage.[181] However, the LAA lies in close relation to the free wall of the left ventricle, and thus the LAA's emptying and filling, which determines its degree of blood stagnation, may be helped by the motion of the wall of the left ventricle if there is good ventricular function.[182]

Dementia

Atrial fibrillation has been independently associated with a higher risk of developing cognitive impairment, vascular dementia, and Alzheimer disease and with elevated levels of neurofilament light chain in blood, a biomarker indicating neuroaxonal injury.[183] [176] [184] Several mechanisms for this association have been proposed, including silent small blood clots (subclinical microthrombi) traveling to the brain resulting in small ischemic strokes without symptoms, altered blood flow to the brain, inflammation, clinically silent small bleeds in the brain, and genetic factors.[185] [176] [184] Tentative evidence suggests that effective anticoagulation with direct oral anticoagulants or warfarin may be somewhat protective against AF-associated dementia and evidence of silent ischemic strokes on MRI but this remains an active area of investigation.[176] [184]

Epidemiology

Atrial fibrillation is the most common arrhythmia and affects more than 33 million people worldwide.[18] [26] In Europe and North America,, it affects about 2% to 3% of the population.[25] This is an increase from 0.4 to 1% of the population around 2005.[26] In the developing world, rates are about 0.6% for males and 0.4% for females.[25] The number of people diagnosed with AF has increased due to better detection of silent AF and increasing age and conditions that predispose to it.[186]

It also accounts for one-third of hospital admissions for cardiac rhythm disturbances,[26] and the rate of admissions for AF has risen in recent years.[187] AF is the cause for 20% to 30% of all ischemic strokes.[186] After a transient ischemic attack or stroke, about 11% are found to have a new diagnosis of atrial fibrillation.[188] 3% to 11% of patients with AF have structurally normal hearts.[189] Approximately 2.2 million individuals in the United States and 4.5 million in the European Union have AF.[26]

The number of new cases each year of AF increases with age. In people older than 80 years, it affects about 8%.[26] In contrast, in younger people the prevalence is estimated to be 0.05% and is associated with congenital heart disease or structural heart disease in this demographic.[190] As of 2001, it was anticipated that in developed countries, the number of people with atrial fibrillation was likely to increase during the following 50 years, due to the growing proportion of elderly people.[191]

Gender

Atrial fibrillation is more common in men than in women when reviewed in European and North American populations.[192] In developed and developing countries, there is also a higher rate in men than in women. The risk factors associated with AF are also distributed differently according to gender. In men, coronary disease is more frequent, while in women, high systolic blood pressure and valvular heart disease are more prevalent.[55]

Ethnicity

Rates of AF are lower in populations of African descent than in populations of European descent. African descent is associated with a protective effect for AF, due to the lower presence of SNPs with guanine alleles. European ancestry has more frequent mutations. The variant rs4611994 for the gene PITX2 is associated with risk of AF in African and European populations. Hispanic and Asian populations have a lower risk of AF than European populations. The risk of AF in non-European populations is associated with characteristic risk factors of these populations, such as hypertension.[193]

Young people

Atrial fibrillation is an uncommon condition in children but sometimes occurs in association with certain inherited and acquired conditions. Congenital heart disease and rheumatic fever are the most common causes of atrial fibrillation in children. Other inherited heart conditions associated with the development of atrial fibrillation in children include Brugada syndrome, short QT syndrome, Wolff Parkinson White syndrome, and other forms of supraventricular tachycardia (e.g., AV nodal reentrant tachycardia).[190] Adults who survived congenital heart disease have an increased risk of developing AF. In particular, people who had atrial septal defects, Tetralogy of Fallot, or Ebstein's anomaly, and those who underwent the Fontan procedure, are at higher risk with prevalence rates of up to 30% depending on the heart's anatomy and the person's age.[32]

History

Because the diagnosis of atrial fibrillation requires measurement of the electrical activity of the heart, atrial fibrillation was not truly described until 1874, when Edmé Félix Alfred Vulpian observed the irregular atrial electrical behavior that he termed "fremissement fibrillaire" in dog hearts.[194] In the mid-18th century, Jean-Baptiste de Sénac made note of dilated, irritated atria in people with mitral stenosis.[195] The irregular pulse associated with AF was first recorded in 1876 by Carl Wilhelm Hermann Nothnagel and termed "delirium cordis", stating that "[I]n this form of arrhythmia the heartbeats follow each other in complete irregularity. At the same time, the height and tension of the individual pulse waves are continuously changing".[196] Correlation of delirium cordis with the loss of atrial contraction, as reflected in the loss of a waves in the jugular venous pulse, was made by Sir James MacKenzie in 1904.[197] Willem Einthoven published the first ECG showing AF in 1906.[198] The connection between the anatomic and electrical manifestations of AF and the irregular pulse of delirium cordis was made in 1909 by Carl Julius Rothberger, Heinrich Winterberg, and Sir Thomas Lewis.[199] [200] [201]

Other animals

Atrial fibrillation occurs in other animals, including cats, dogs, and horses.[202] [203] Unlike humans, dogs rarely develop the complications that stem from blood clots breaking off from inside the heart and traveling through the arteries to distant sites (thromboembolic complications).[202] Cats rarely develop atrial fibrillation but appear to have a higher risk of thromboembolic complications than dogs.[202]

Cats and dogs with atrial fibrillation often have underlying structural heart disease that predisposes them to the condition.[202] The medications used in animals for atrial fibrillation are largely similar to those used in humans.[202] Electrical cardioversion is occasionally performed in these animals, but the need for general anesthesia limits its use.[202] Standardbred horses appear to be genetically susceptible to developing atrial fibrillation.[203] Horses that develop atrial fibrillation often have minimal or no underlying heart disease, and the presence of atrial fibrillation in horses can adversely affect physical performance.[203]

Further reading

External links

Notes and References

  1. Web site: Atrial fibrillation or flutter: MedlinePlus Medical Encyclopedia . medlineplus.gov . 28 May 2019 .
  2. Book: Hui D, Leung AA, Padwal R . Approach to Internal Medicine: A Resource Book for Clinical Practice . 2015 . Springer . 978-3-319-11821-5 . 45 . live . https://web.archive.org/web/20170908144250/https://books.google.com/books?id=35uoCgAAQBAJ&pg=PA45 . 8 September 2017 .
  3. Li X, Liu Z, Jiang X, Xia R, Li Y, Pan X, Yao Y, Fan X . Global, regional, and national burdens of atrial fibrillation/flutter from 1990 to 2019: An age-period-cohort analysis using the Global Burden of Disease 2019 study . Journal of Global Health . 13 . 04154 . November 2023 . 37988383 . 10662782 . 10.7189/jogh.13.04154 .
  4. Web site: Heart Disease Other Related Conditions . cdc.gov . 19 February 2015 . 3 September 2014 . live . https://web.archive.org/web/20150214234446/http://www.cdc.gov/heartdisease/other_conditions.htm . 14 February 2015 .
  5. Bun SS, Latcu DG, Marchlinski F, Saoudi N . Atrial flutter: more than just one of a kind . European Heart Journal . 36 . 35 . 2356–2363 . September 2015 . 25838435 . 10.1093/eurheartj/ehv118 . Oxford University Press (OUP) . free .
  6. Book: Gray D . Chamberlain's Symptoms and Signs in Clinical Medicine: An Introduction to Medical Diagnosis . 2010 . Hodder Arnold . London . 978-0-340-97425-4 . 70–71 . 13th .
  7. Book: Richard D. Urman . Linda S. Aglio . Robert W. Lekowski . Essential clinical anesthesia review: keywords, questions and answers for the boards . 2015 . 978-1-107-68130-9 . 480 . Cambridge University Press . live . https://web.archive.org/web/20170908144250/https://books.google.com/books?id=VJzWBQAAQBAJ&pg=PA480 . 8 September 2017 .
  8. McGarry TJ, Narayan SM . The anatomical basis of pulmonary vein reconnection after ablation for atrial fibrillation: wounds that never felt a scar? . . 50 . 10. 939–941 . 2012 . 10.1016/j.jacc.2011.11.032 . 3393092 . 22381430 .
  9. Stavrakis S, Po S . Ganglionated Plexi Ablation: Physiology and Clinical Applications . Arrhythmia & Electrophysiology Review . 6 . 4 . 186–190 . 2017. 10.15420/aer2017.26.1 . 5739885 . 29326833 .
  10. Naksuk N, Padmanabhan D, Asirvatham SJ . Left Atrial Appendage: Embryology, Anatomy, Physiology, Arrhythmia and Therapeutic Intervention . . 2 . 4 . 403-412 . 2016 . 10.1016/j.jacep.2016.06.006 . 29759858 .
  11. Eranki A, Wilson-Smith A, Manganas C . Mid term freedom from atrial fibrillation following hybrid ablation, a systematic review and meta analysis . . 18 . 1 . 155 . 2023 . 10.1186/s13019-023-02189-2 . free . 10114378 . 37076929 .
  12. Nguyen TN, Hilmer SN, Cumming RG . Review of epidemiology and management of atrial fibrillation in developing countries . International Journal of Cardiology . 167 . 6 . 2412–2420 . September 2013 . 23453870 . 10.1016/j.ijcard.2013.01.184 .
  13. Anumonwo JM, Kalifa J . Risk factors and genetics of atrial fibrillation . Cardiology Clinics . 32 . 4 . 485–494 . November 2014 . 25443231 . 10.1016/j.ccl.2014.07.007 .
  14. Rafaqat S, Rafaqat S, Rafaqat S . The Role of Major Biomarkers of Stress in Atrial Fibrillation: A Literature Review . The Journal of Innovations in Cardiac Rhythm Management . 14 . 2 . 5355–5364 . February 2023 . 36874560 . 9983621 . 10.19102/icrm.2023.14025 .
  15. Mischke K, Knackstedt C, Marx N, Vollmann D . Insights into atrial fibrillation . Minerva Medica . 104 . 2 . 119–130 . April 2013 . 23514988 .
  16. Europace . 10.1093/europace/euae102.254 . Is thyroid function testing necessary in all cases of new onset atrial fibrillation diagnosed in the emergency department? - a real-life study . 2024 . 26 . Hytting J, Celik S, Bodestrom Eriksson L, Mallios P, Digerfeldt C, Waldemar A, Wijkman M, Hubbert L . Suppl 1 . euae102.254 . 11120881 .
  17. Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM . Atrial fibrillation: stroke prevention in focus . Australian Critical Care . 27 . 2 . 92–98 . May 2014 . 24054541 . 10.1016/j.aucc.2013.08.002 .
  18. Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, Noseworthy PA, Pack QR, Sanders P, Trulock KM . Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association . Circulation . 141 . 16 . e750–e772 . April 2020 . 32148086 . 10.1161/CIR.0000000000000748 . free .
  19. Oishi ML, Xing S . Atrial fibrillation: management strategies in the emergency department . Emergency Medicine Practice . 15 . 2 . 1–26; quiz 27 . February 2013 . 23369365 .
  20. Amerena JV, Walters TE, Mirzaee S, Kalman JM . Update on the management of atrial fibrillation . The Medical Journal of Australia . 199 . 9 . 592–597 . November 2013 . 24182224 . 10.5694/mja13.10191 . free .
  21. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GY, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC . European Heart Journal . 42 . 5 . 373–498 . February 2021 . 32860505 . 10.1093/eurheartj/ehaa612 . free . free . 11379/546100 .
  22. Freedman B, Potpara TS, Lip GY . Stroke prevention in atrial fibrillation . Lancet . 388 . 10046 . 806–817 . August 2016 . 27560276 . 10.1016/S0140-6736(16)31257-0 . 5578741 .
  23. Steinberg BA, Piccini JP . Anticoagulation in atrial fibrillation . BMJ . 348 . g2116 . April 2014 . 24733535 . 4688652 . 10.1136/bmj.g2116 .
  24. Munger TM, Wu LQ, Shen WK . Atrial fibrillation . Journal of Biomedical Research . 28 . 1 . 1–17 . January 2014 . 24474959 . 3904170 . 10.7555/JBR.28.20130191 .
  25. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S . Epidemiology of atrial fibrillation: European perspective . Clinical Epidemiology . 6 . 213–220 . 2014 . 24966695 . 4064952 . 10.2147/CLEP.S47385 . free .
  26. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL . ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society . Circulation . 114 . 7 . e257–e354 . August 2006 . 16908781 . 10.1161/CIRCULATIONAHA.106.177292 . free .
  27. ((GBD 2015 Mortality and Causes of Death Collaborators)) . Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1459–1544 . October 2016 . 27733281 . 5388903 . 10.1016/s0140-6736(16)31012-1 .
  28. ((GBD 2013 Mortality and Causes of Death Collaborators)) . Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet . 385 . 9963 . 117–171 . January 2015 . 25530442 . 4340604 . 10.1016/S0140-6736(14)61682-2 .
  29. Gutierrez C, Blanchard DG . Atrial fibrillation: diagnosis and treatment . American Family Physician . 83 . 1 . 61–68 . January 2011 . 21888129 . live . Review . https://web.archive.org/web/20131224120005/http://www.aafp.org/afp/2011/0101/p61.html . 24 December 2013 .
  30. Kim SH, Lim KR, Chun KJ . Higher heart rate variability as a predictor of atrial fibrillation in patients with hypertensione . . 12 . 1 . 3702 . 2022 . 10.1038/s41598-022-07783-3 . 8904557 . 35260686 . 2022NatSR..12.3702K .
  31. Marelli A, Miller SP, Marino BS, Jefferson AL, Newburger JW . Brain in Congenital Heart Disease Across the Lifespan: The Cumulative Burden of Injury . Circulation . 133 . 20 . 1951–1962 . May 2016 . 27185022 . 5519142 . 10.1161/CIRCULATIONAHA.115.019881 .
  32. Ebrahim MA, Escudero CA, Kantoch MJ, Vondermuhll IF, Atallah J . Insights on Atrial Fibrillation in Congenital Heart Disease . The Canadian Journal of Cardiology . 34 . 11 . 1531–1533 . November 2018 . 30404756 . 10.1016/j.cjca.2018.08.010 . 53213100 .
  33. Kuipers S, Klein Klouwenberg PM, Cremer OL . Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review . Critical Care . 18 . 6 . 688 . December 2014 . 25498795 . 4296551 . 10.1186/s13054-014-0688-5 . Systematic Review . free .
  34. Walkey AJ, Hogarth DK, Lip GY . Optimizing atrial fibrillation management: from ICU and beyond . Chest . 148 . 4 . 859–864 . October 2015 . 25951122 . 4594627 . 10.1378/chest.15-0358 . Review .
  35. Abed HS, Wittert GA . Obesity and atrial fibrillation . Obesity Reviews . 14 . 11 . 929–938 . November 2013 . 23879190 . 10.1111/obr.12056 . 25479450 .
  36. Hoyer FF, Lickfett LM, Mittmann-Braun E, Ruland C, Kreuz J, Pabst S, Schrickel J, Juergens U, Tasci S, Nickenig G, Skowasch D . High prevalence of obstructive sleep apnea in patients with resistant paroxysmal atrial fibrillation after pulmonary vein isolation . Journal of Interventional Cardiac Electrophysiology . 29 . 1 . 37–41 . October 2010 . 20714922 . 10.1007/s10840-010-9502-8 . 11129249 .
  37. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK . Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation . Journal of the American College of Cardiology . 49 . 5 . 565–571 . February 2007 . 17276180 . 10.1016/j.jacc.2006.08.060 .
  38. Magnani JW, Hylek EM, Apovian CM . Obesity begets atrial fibrillation: a contemporary summary . Circulation . 128 . 4 . 401–405 . July 2013 . 23877062 . 3866045 . 10.1161/CIRCULATIONAHA.113.001840 .
  39. Palmeiro C, Davila MI, Bhat M, Frishman WH, Weiss IA . Subclinical hyperthyroidism and cardiovascular risk: recommendations for treatment . Cardiology in Review . 21 . 6 . 300–308 . December 2013 . 23563523 . 10.1097/CRD.0b013e318294f6f1 . 2311111 .
  40. Cheng M, Hu Z, Lu X, Huang J, Gu D . Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies . The Canadian Journal of Cardiology . 30 . 4 . 448–454 . April 2014 . 24680173 . 10.1016/j.cjca.2013.12.026 .
  41. Voskoboinik A, Prabhu S, Ling LH, Kalman JM, Kistler PM . Alcohol and Atrial Fibrillation: A Sobering Review . Journal of the American College of Cardiology . 68 . 23 . 2567–2576 . December 2016 . 27931615 . 10.1016/j.jacc.2016.08.074 . free .
  42. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH . Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes . Circulation Research . 120 . 9 . 1501–1517 . April 2017 . 28450367 . 5500874 . 10.1161/CIRCRESAHA.117.309732 . Review .
  43. Du X, Dong J, Ma C . Is Atrial Fibrillation a Preventable Disease? . Journal of the American College of Cardiology . 69 . 15 . 1968–1982 . April 2017 . 28408027 . 10.1016/j.jacc.2017.02.020 . Review . free .
  44. Wilhelm M . Atrial fibrillation in endurance athletes . European Journal of Preventive Cardiology . 21 . 8 . 1040–1048 . August 2014 . 23610454 . 10.1177/2047487313476414 . 22065631 . free .
  45. Elliott AD, Mahajan R, Pathak RK, Lau DH, Sanders P . Exercise Training and Atrial Fibrillation: Further Evidence for the Importance of Lifestyle Change . Circulation . 133 . 5 . 457–459 . February 2016 . 26733608 . 10.1161/CIRCULATIONAHA.115.020800 . 2475456 .
  46. Web site: Night shift work is linked to increased risk of heart problems . Escardio . 16 August 2021.
  47. Hazarapetyan L, Zelveian PH, Grigoryan S . Inflammation and Coagulation are Two Interconnected Pathophysiological Pathways in Atrial Fibrillation Pathogenesis . . 16 . 4967–4975 . 2023 . 10.2147/JIR.S429892 . free . 10625332 . 37927962 .
  48. Chu H, Guo X, Wang Y . Causal relationship between immune cells and atrial fibrillation: A Mendelian randomization study . . 103 . 19 . e38079 . 2024 . 10.1097/MD.0000000000038079 . 11081550 . 38728471 .
  49. Fox CS, Parise H, D'Agostino RB, Lloyd-Jones DM, Vasan RS, Wang TJ, Levy D, Wolf PA, Benjamin EJ . Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring . JAMA . 291 . 23 . 2851–2855 . June 2004 . 15199036 . 10.1001/jama.291.23.2851 . free .
  50. Roberts JD, Gollob MH . A contemporary review on the genetic basis of atrial fibrillation . Methodist DeBakey Cardiovascular Journal . 10 . 1 . 18–24 . 2014 . 24932358 . 4051329 . 10.14797/mdcj-10-1-18 .
  51. Howlett PJ, Hatch FS, Alexeenko V, Jabr RI, Leatham EW, Fry CH . Diagnosing Paroxysmal Atrial Fibrillation: Are Biomarkers the Solution to This Elusive Arrhythmia? . BioMed Research International . 2015 . 910267 . 2015 . 26229966 . 4502272 . 10.1155/2015/910267 . free .
  52. Saffitz JE . Connexins, conduction, and atrial fibrillation . The New England Journal of Medicine . 354 . 25 . 2712–2714 . June 2006 . 16790707 . 10.1056/NEJMe068088 .
  53. Web site: OMIM Online Mendelian Inheritance of Man . 24 August 2010 . The National Center for Biotechnology Information . live . https://web.archive.org/web/20130616044027/http://www.ncbi.nlm.nih.gov/omim?term=atrial%20fibrillation%20%5Btitle%5D . 16 June 2013 .
  54. Shimizu W . [Atrial fibrillation and genetic abnormalities] . Nihon Rinsho. Japanese Journal of Clinical Medicine . 71 . 1 . 161–166 . January 2013 . 23631189 .
  55. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH . Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes . Circulation Research . 120 . 9 . 1501–1517 . April 2017 . 28450367 . 5500874 . 10.1161/CIRCRESAHA.117.309732 . 3 .
  56. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D . Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation . The New England Journal of Medicine . 354 . 25 . 2677–2688 . June 2006 . 16790700 . 10.1056/NEJMoa052800 . free .
  57. Shoemaker MB, Bollmann A, Lubitz SA, Ueberham L, Saini H, Montgomery J, Edwards T, Yoneda Z, Sinner MF, Arya A, Sommer P, Delaney J, Goyal SK, Saavedra P, Kanagasundram A, Whalen SP, Roden DM, Hindricks G, Ellis CR, Ellinor PT, Darbar D, Husser D . Common genetic variants and response to atrial fibrillation ablation . Circulation: Arrhythmia and Electrophysiology . 8 . 2 . 296–302 . April 2015 . 25684755 . 4731871 . 10.1161/CIRCEP.114.001909 .
  58. Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC, Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H, Campbell A, Cappola TP, Carlquist J, Chasman DI, Chen LY, Chen YI, Choi EK, Choi SH, Christophersen IE, Chung MK, Cole JW, Conen D, Cook J, Crijns HJ, Cutler MJ, Damrauer SM, Daniels BR, Darbar D, Delgado G, Denny JC, Dichgans M, Dörr M, Dudink EA, Dudley SC, Esa N, Esko T, Eskola M, Fatkin D, Felix SB, Ford I, Franco OH, Geelhoed B, Grewal RP, Gudnason V, Guo X, Gupta N, Gustafsson S, Gutmann R, Hamsten A, Harris TB, Hayward C, Heckbert SR, Hernesniemi J, Hocking LJ, Hofman A, Horimoto AR, Huang J, Huang PL, Huffman J, Ingelsson E, Ipek EG, Ito K, Jimenez-Conde J, Johnson R, Jukema JW, Kääb S, Kähönen M, Kamatani Y, Kane JP, Kastrati A, Kathiresan S, Katschnig-Winter P, Kavousi M, Kessler T, Kietselaer BL, Kirchhof P, Kleber ME, Knight S, Krieger JE, Kubo M, Launer LJ, Laurikka J, Lehtimäki T, Leineweber K, Lemaitre RN, Li M, Lim HE, Lin HJ, Lin H, Lind L, Lindgren CM, Lokki ML, London B, Loos RJ, Low SK, Lu Y, Lyytikäinen LP, Macfarlane PW, Magnusson PK, Mahajan A, Malik R, Mansur AJ, Marcus GM, Margolin L, Margulies KB, März W, McManus DD, Melander O, Mohanty S, Montgomery JA, Morley MP, Morris AP, Müller-Nurasyid M, Natale A, Nazarian S, Neumann B, Newton-Cheh C, Niemeijer MN, Nikus K, Nilsson P, Noordam R, Oellers H, Olesen MS, Orho-Melander M, Padmanabhan S, Pak HN, Paré G, Pedersen NL, Pera J, Pereira A, Porteous D, Psaty BM, Pulit SL, Pullinger CR, Rader DJ, Refsgaard L, Ribasés M, Ridker PM, Rienstra M, Risch L, Roden DM, Rosand J, Rosenberg MA, Rost N, Rotter JI, Saba S, Sandhu RK, Schnabel RB, Schramm K, Schunkert H, Schurman C, Scott SA, Seppälä I, Shaffer C, Shah S, Shalaby AA, Shim J, Shoemaker MB, Siland JE, Sinisalo J, Sinner MF, Slowik A, Smith AV, Smith BH, Smith JG, Smith JD, Smith NL, Soliman EZ, Sotoodehnia N, Stricker BH, Sun A, Sun H, Svendsen JH, Tanaka T, Tanriverdi K, Taylor KD, Teder-Laving M, Teumer A, Thériault S, Trompet S, Tucker NR, Tveit A, Uitterlinden AG, Van Der Harst P, Van Gelder IC, Van Wagoner DR, Verweij N, Vlachopoulou E, Völker U, Wang B, Weeke PE, Weijs B, Weiss R, Weiss S, Wells QS, Wiggins KL, Wong JA, Woo D, Worrall BB, Yang PS, Yao J, Yoneda ZT, Zeller T, Zeng L, Lubitz SA, Lunetta KL, Ellinor PT . Multi-ethnic genome-wide association study for atrial fibrillation . Nature Genetics . 50 . 9 . 1225–1233 . June 2018 . 29892015 . 6136836 . 10.1038/s41588-018-0133-9 .
  59. Ahlberg G, Refsgaard L, Lundegaard PR, Andreasen L, Ranthe MF, Linscheid N, Nielsen JB, Melbye M, Haunsø S, Sajadieh A, Camp L, Olesen SP, Rasmussen S, Lundby A, Ellinor PT, Holst AG, Svendsen JH, Olesen MS . Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation . Nature Communications . 9 . 1 . 4316 . October 2018 . 30333491 . 6193003 . 10.1038/s41467-018-06618-y . 2018NatCo...9.4316A .
  60. Choi SH, Jurgens SJ, Weng LC, Pirruccello JP, Roselli C, Chaffin M, Lee CJ, Hall AW, Khera AV, Lunetta KL, Lubitz SA, Ellinor PT . Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank . Circulation Research . 126 . 2 . 200–209 . January 2020 . 31691645 . 7007701 . 10.1161/CIRCRESAHA.119.315686 .
  61. Brcic L, Underwood JFG, Kendall KM et al. (2020) Medical and neurobehavioural phenotypes in carriers of X-linked ichthyosis-associated genetic deletions in the UK Biobank. Journal of Medical Genetics 0:1-7 doi:10.1136/jmedgenet-2019-106676 URL:https://jmg.bmj.com/content/early/2020/04/23/jmedgenet-2019-106676.long
  62. Wren GH, Baker E, Underwood JFG, Humby T, Thompson AR, Kirov G, Escott-Price V, Davies W. (2022) Characterising heart rhythm abnormalities associated with Xp22.31 deletion Journal of Medical Genetics doi:10.1136/jmg-2022-108862 PMID 36379544 URL:https://jmg.bmj.com/content/early/2022/11/15/jmg-2022-108862
  63. Thorp AA, Owen N, Neuhaus M, Dunstan DW . Sedentary behaviors and subsequent health outcomes in adults a systematic review of longitudinal studies, 1996-2011 . American Journal of Preventive Medicine . 41 . 2 . 207–215 . August 2011 . 21767729 . 10.1016/j.amepre.2011.05.004 .
  64. Mohanty S, Mohanty P, Tamaki M, Natale V, Gianni C, Trivedi C, Gokoglan Y, DI Biase L, Natale A . Differential Association of Exercise Intensity With Risk of Atrial Fibrillation in Men and Women: Evidence from a Meta-Analysis . Journal of Cardiovascular Electrophysiology . 27 . 9 . 1021–1029 . September 2016 . 27245609 . 10.1111/jce.13023 . 206025944 .
  65. Abdulla J, Nielsen JR . Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis . Europace . 11 . 9 . 1156–1159 . September 2009 . 19633305 . 10.1093/europace/eup197 . free .
  66. D'Andrea A, Riegler L, Cocchia R, Scarafile R, Salerno G, Gravino R, Golia E, Vriz O, Citro R, Limongelli G, Calabrò P, Di Salvo G, Caso P, Russo MG, Bossone E, Calabrò R . Left atrial volume index in highly trained athletes . American Heart Journal . 159 . 6 . 1155–1161 . June 2010 . 20569734 . 10.1016/j.ahj.2010.03.036 .
  67. Hergens MP, Galanti R, Hansson J, Fredlund P, Ahlbom A, Alfredsson L, Bellocco R, Eriksson M, Fransson EI, Hallqvist J, Jansson JH, Knutsson A, Pedersen N, Lagerros YT, Ostergren PO, Magnusson C . Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation . Epidemiology . 25 . 6 . 872–876 . November 2014 . 25166877 . 10.1097/EDE.0000000000000169 . 24080017 . free .
  68. Storz MA, Helle P . Atrial fibrillation risk factor management with a plant-based diet: A review . Journal of Arrhythmia . 35 . 6 . 781–788. 2019 . 10.1002/joa3.12254 . 6898539 . 31844466.
  69. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BH, Gudnason V, Heckbert SR, Benjamin EJ . Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium . Journal of the American Heart Association . 2 . 2 . e000102 . March 2013 . 23537808 . 3647274 . 10.1161/JAHA.112.000102 .
  70. Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Larsen TB, Lip GY, Løchen ML, Marín F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, Van Wagoner DR, Fauchier L, Savelieva I, Goette A, Agewall S, Chiang CE, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Marques-Vidal PM, Faggiano P, Schmid JP, Abreu A . European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS) . Europace . 19 . 2 . 190–225 . February 2017 . 28175283 . 6279109 . 10.1093/europace/euw242 . Review .
  71. Shen MJ, Arora R, Jalife J . Atrial Myopathy . JACC. Basic to Translational Science . 4 . 5 . 640–654 . September 2019 . 31768479 . 6872845 . 10.1016/j.jacbts.2019.05.005 .
  72. Waks JW, Josephson ME . Mechanisms of Atrial Fibrillation - Reentry, Rotors and Reality . Arrhythmia & Electrophysiology Review . 3 . 2 . 90–100 . August 2014 . 26835073 . 4711504 . 10.15420/aer.2014.3.2.90 .
  73. Pellman J, Sheikh F . Atrial fibrillation: mechanisms, therapeutics, and future directions . Comprehensive Physiology . 5 . 2 . 649–665 . April 2015 . 25880508 . 5240842 . 10.1002/cphy.c140047 . 978-0-470-65071-4 .
  74. Book: Klabunde R . Cardiovascular Physiology Concepts . Lippincott Williams & Wilkins . 2005 . 25, 28 . limited . 978-0-7817-5030-1 .
  75. Pay L, Yumurtaş AÇ, Satti DI, Hui JM, Chan JS, Mahalwar G, Lee YH, Tezen O, Birdal O, Inan D, Özkan E, Tse G, Çinier G . Arrhythmias Beyond Atrial Fibrillation Detection Using Smartwatches: A Systematic Review . Anatolian Journal of Cardiology . 27 . 3 . 126–131 . March 2023 . 36856589 . 9995551 . 10.14744/anatoljcardiol.2023.2799 . Kare Publishing .
  76. Khan AA, Thomas GN, Lip G, Shantsila A . Endothelial function in patients with atrial fibrillation . . 52 . 1–2 . 1–11 . 2020 . 10.1080/07853890.2019.1711158 . 7877921 . 31903788 .
  77. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GY, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC . European Heart Journal . 42 . 5 . 373–498 . February 2021 . 32860505 . 10.1093/eurheartj/ehaa612 . free . free . ESC Scientific Document Group . 1887/3279676 .
  78. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani H, Hendriks J, Hespe C, Hung J, Kalman JM, Sanders P, Worthington J, Yan TD, Zwar N . National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018 . Heart, Lung & Circulation . 27 . 10 . 1209–1266 . October 2018 . 30077228 . 10.1016/j.hlc.2018.06.1043 . free . free . 10536/DRO/DU:30157490 .
  79. Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ . A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference . Europace . 18 . 1 . 37–50 . January 2016 . 26481149 . 10.1093/europace/euv304 .
  80. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, Banerjee A, Gorenek B, Brachmann J, Varma N, Glotz de Lima G, Kalman J, Claes N, Lobban T, Lane D, Lip GY, Boriani G . Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE) . Europace . 19 . 10 . 1589–1623 . October 2017 . 29048522 . 10.1093/europace/eux177 . free .
  81. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, Albert CM, Anderson CS, Antoniou S, Benjamin EJ, Boriani G, Brachmann J, Brandes A, Chao TF, Conen D, Engdahl J, Fauchier L, Fitzmaurice DA, Friberg L, Gersh BJ, Gladstone DJ, Glotzer TV, Gwynne K, Hankey GJ, Harbison J, Hillis GS, Hills MT, Kamel H, Kirchhof P, Kowey PR, Krieger D, Lee VW, Levin LÅ, Lip GY, Lobban T, Lowres N, Mairesse GH, Martinez C, Neubeck L, Orchard J, Piccini JP, Poppe K, Potpara TS, Puererfellner H, Rienstra M, Sandhu RK, Schnabel RB, Siu CW, Steinhubl S, Svendsen JH, Svennberg E, Themistoclakis S, Tieleman RG, Turakhia MP, Tveit A, Uittenbogaart SB, Van Gelder IC, Verma A, Wachter R, Yan BP . Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration . Circulation . 135 . 19 . 1851–1867 . May 2017 . 28483832 . 10.1161/CIRCULATIONAHA.116.026693 . ((AF-Screen Collaborators)) . 207655707 . free . 11380/1139441 . free .
  82. Stott DJ, Dewar RI, Garratt CJ, Griffith KE, Harding NJ, James MA, Lane DA, Petty DR, Smith PA, Somerville MH, Trueland J . RCPE UK Consensus Conference on 'approaching the comprehensive management of atrial fibrillation: evolution or revolution?' . The Journal of the Royal College of Physicians of Edinburgh . 42 . 1 . 34–35 . March 2012 . 22441062 . 10.4997/JRCPE.2012.S01 . free .
  83. Hobbs FR, Taylor CJ, Jan Geersing G, Rutten FH, Brouwer JR . European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care . European Journal of Preventive Cardiology . 23 . 5 . 460–473 . March 2016 . 25701017 . 4766963 . 10.1177/2047487315571890 . free .
  84. Web site: Reports and Publications HIQA . www.hiqa.ie.
  85. Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A, Fitzmaurice DA, Gomez-Doblas JJ, Harbison J, Healey JS, Hobbs FD, Kaasenbrood F, Keen W, Lee VW, Lindholt JS, Lip GY, Mairesse GH, Mant J, Martin JW, Martín-Rioboó E, McManus DD, Muñiz J, Münzel T, Nakamya J, Neubeck L, Orchard JJ, Pérula de Torres LÁ, Proietti M, Quinn FR, Roalfe AK, Sandhu RK, Schnabel RB, Smyth B, Soni A, Tieleman R, Wang J, Wild PS, Yan BP, Freedman B . Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals . PLOS Medicine . 16 . 9 . e1002903 . September 2019 . 31553733 . 6760766 . 10.1371/journal.pmed.1002903 . free .
  86. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB . Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement . JAMA . 320 . 5 . 478–484 . August 2018 . 30088016 . 10.1001/jama.2018.10321 . free . US Preventive Services Task Force. .
  87. Godin R, Yeung C, Baranchuk A, Guerra P, Healey JS . Screening for Atrial Fibrillation Using a Mobile, Single-Lead Electrocardiogram in Canadian Primary Care Clinics . The Canadian Journal of Cardiology . 35 . 7 . 840–845 . July 2019 . 31292082 . 10.1016/j.cjca.2019.03.024 . 132597318 .
  88. Kaasenbrood F, Hollander M, Rutten FH, Gerhards LJ, Hoes AW, Tieleman RG . Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination . Europace . 18 . 10 . 1514–1520 . October 2016 . 26851813 . 5072135 . 10.1093/europace/euv426 .
  89. Orchard J, Neubeck L, Freedman B, Li J, Webster R, Zwar N, Gallagher R, Ferguson C, Lowres N . eHealth Tools to Provide Structured Assistance for Atrial Fibrillation Screening, Management, and Guideline-Recommended Therapy in Metropolitan General Practice: The AF - SMART Study . Journal of the American Heart Association . 8 . 1 . e010959 . January 2019 . 30590964 . 6405712 . 10.1161/JAHA.118.010959 . free .
  90. Orchard J, Lowres N, Freedman SB, Ladak L, Lee W, Zwar N, Peiris D, Kamaladasa Y, Li J, Neubeck L . Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): A feasibility study . European Journal of Preventive Cardiology . 23 . 2 suppl . 13–20 . October 2016 . 27892421 . 10.1177/2047487316670255 . free .
  91. Orchard J, Freedman SB, Lowres N, Peiris D, Neubeck L . iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study . Australian Family Physician . 43 . 5 . 315–319 . May 2014 . 24791776 .
  92. Orchard J, Li J, Freedman B, Webster R, Salkeld G, Hespe C, Gallagher R, Patel A, Kamel B, Neubeck L, Lowres N . Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening . Journal of the American Heart Association . 9 . 18 . e017080 . September 2020 . 32865129 . 7726973 . 10.1161/JAHA.120.017080 . free .
  93. Book: Issa ZF, Miller JM, Zipes DP . Clinical arrhythmology and electrophysiology: a companion to Braunwald's heart disease . 2009 . Saunders . Philadelphia . 978-1-4160-5998-1 . 221 . live . https://web.archive.org/web/20170908144250/https://books.google.com/books?id=a8s8nd2JAiwC&pg=PA221 . 8 September 2017 .
  94. Romero J, Cao JJ, Garcia MJ, Taub CC . Cardiac imaging for assessment of left atrial appendage stasis and thrombosis . Nature Reviews. Cardiology . 11 . 8 . 470–480 . August 2014 . 24913058 . 10.1038/nrcardio.2014.77 . 29114242 .
  95. Ramlawi B, Abu Saleh WK, Edgerton J . The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation . Methodist DeBakey Cardiovascular Journal . 11 . 2 . 100–103 . 2015 . 26306127 . 4547664 . 10.14797/mdcj-11-2-100 .
  96. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW . 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society . Heart Rhythm . 16 . 8 . e66–e93 . August 2019 . 30703530 . 10.1016/j.hrthm.2019.01.024 . Review . free .
  97. Prystowsky EN, Padanilam BJ, Fogel RI . Treatment of Atrial Fibrillation . JAMA . 314 . 3 . 278–288 . July 2015 . 26197188 . 10.1001/jama.2015.7505 . 205070036 .
  98. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation . The Cochrane Database of Systematic Reviews . 2019 . 9 . CD005049 . September 2019 . 31483500 . 6738133 . 10.1002/14651858.CD005049.pub5 .
  99. Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, Gumprecht J, Kozieł M, Yang PS, Guo Y, Lip GY, Proietti M . Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients . Thrombosis and Haemostasis . 122 . 3 . 406–414 . March 2022 . 34020488 . 10.1055/A-1515-9630 . free . free . 2434/887644 .
  100. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GY . Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway . The American Journal of Medicine . 131 . 11 . 1359–1366.e6 . November 2018 . 30153428 . 10.1016/j.amjmed.2018.06.012 . 2183/31714 . 52114134 .
  101. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GY . Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial . Journal of the American Heart Association . 9 . 10 . e014932 . May 2020 . 32370588 . 7660878 . 10.1161/JAHA.119.014932 . free .
  102. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GY . Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort . Mayo Clinic Proceedings . 94 . 7 . 1261–1267 . July 2019 . 30551910 . 10.1016/j.mayocp.2018.10.022 . 54623946 .
  103. Lip GY . The ABC pathway: an integrated approach to improve AF management . Nature Reviews. Cardiology . 14 . 11 . 627–628 . November 2017 . 28960189 . 10.1038/nrcardio.2017.153 . 36013527 .
  104. Stroke Prevention in Patients With Atrial Fibrillation: A Systematic Review Update . Sanders . Gillian D. . Lowenstern . Angela . 2018-10-30 . Agency for Healthcare Resarch and Quality (AHRQ) . 10.23970/ahrqepccer214 . Borre . Ethan . Chatterjee . Ranee . Goode . Adam . Sharan . Lauren . LaPointe . Nancy M. Allen . Raitz . Giselle . Shah . Bimal.
  105. Verma A, Kalman JM, Callans DJ . Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction . Circulation . 135 . 16 . 1547–1563 . April 2017 . 28416525 . 10.1161/CIRCULATIONAHA.116.026054 . 207646320 . free .
  106. Verdecchia P, Angeli F, Reboldi G . Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies . Circulation Research . 122 . 2 . 352–368 . January 2018 . 29348255 . 10.1161/CIRCRESAHA.117.311402 . 33841631 . free .
  107. Simons SO, Elliott A, Sastry M, Hendriks JM, Arzt M, Rienstra M, Kalman JM, Heidbuchel H, Nattel S, Wesseling G, Schotten U, van Gelder IC, Franssen FM, Sanders P, Crijns HJ, Linz D . Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective . European Heart Journal . 42 . 5 . 532–540 . February 2021 . 33206945 . 10.1093/eurheartj/ehaa822 . free . 1942/35482 .
  108. Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, Boriani G, Harari S, Lip GY, Proietti M . Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients . European Heart Journal . 42 . 35 . 3541–3554 . September 2021 . 34333599 . 10.1093/eurheartj/ehab453 . free . free . 2434/887636 .
  109. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong M, Kotschet E, Kaye D, Taylor AJ, Kistler PM . Alcohol Abstinence in Drinkers with Atrial Fibrillation . The New England Journal of Medicine . 382 . 1 . 20–28 . January 2020 . 31893513 . 10.1056/NEJMoa1817591 . free .
  110. 30480925 . Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Lapointe NA, Raitz G, Shah B, Yapa R, Davis JK . Stroke prevention in patients with atrial fibrillation: a systematic review update. . Rockville (MD) . Agency for Healthcare Research and Quality (US) . October 2018 . Report No.: 18-EHC018-EFReport No.: 2018-SR-04 . AHRQ Comparative Effectiveness Reviews. .
  111. Lip GY, Lane DA . Stroke prevention in atrial fibrillation: a systematic review . JAMA . 313 . 19 . 1950–1962 . May 2015 . 25988464 . 10.1001/jama.2015.4369 .
  112. Zarraga IG, Kron J . Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts . Journal of the American Geriatrics Society . 61 . 1 . 143–150 . January 2013 . 23252345 . 10.1111/jgs.12042 . 34366717 .
  113. Argulian E, Conen D, Messerli FH . Misconceptions and Facts About Atrial Fibrillation . The American Journal of Medicine . 128 . 9 . 938–942 . September 2015 . 25827359 . 10.1016/j.amjmed.2015.02.016 .
  114. Freedman B, Potpara TS, Lip GY . Stroke prevention in atrial fibrillation . Lancet . 388 . 10046 . 806–817 . August 2016 . 27560276 . 10.1016/S0140-6736(16)31257-0 . Review . 5578741 .
  115. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons . Circulation . 140 . 2 . e125–e151 . July 2019 . 30686041 . 10.1161/CIR.0000000000000665 . free .
  116. Andrade JG, Macle L, Nattel S, Verma A, Cairns J . Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines . The Canadian Journal of Cardiology . 33 . 8 . 965–976 . August 2017 . 28754397 . 10.1016/j.cjca.2017.06.002 . Review .
  117. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013) . Circulation Journal . 78 . 8 . 1997–2021 . August 2014 . 24965079 . 10.1253/circj.cj-66-0092 . Review . free . JCS Joint Working Group .
  118. Jung BC, Kim NH, Nam GB, Park HW, On YK, Lee YS, Lim HE, Joung B, Cha TJ, Hwang GS, Oh S, Kim JS . The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society . Korean Circulation Journal . 45 . 1 . 9–19 . January 2015 . 25653698 . 4310986 . 10.4070/kcj.2015.45.1.9 . Review .
  119. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY . Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines . Chest . 141 . 2 Suppl . e531S–e575S . February 2012 . 22315271 . 3278056 . 10.1378/chest.11-2304 . Review .
  120. Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Wei Lim T, Saxena A, Takahashi Y, Siong Teo W . 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation . Journal of Arrhythmia . 33 . 4 . 345–367 . August 2017 . 28765771 . 5529598 . 10.1016/j.joa.2017.05.004 . Review .
  121. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GY, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC . European Heart Journal . 42 . 5 . 373–498 . February 2021 . 32860505 . 10.1093/eurheartj/ehaa612 . free . free . 1887/3279676 .
  122. Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, Healey JS, Bell A, Pilote L, Andrade JG, Mitchell LB, Atzema C, Gladstone D, Sharma M, Verma S, Connolly S, Dorian P, Parkash R, Talajic M, Nattel S, Verma A . 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation . The Canadian Journal of Cardiology . 32 . 10 . 1170–1185 . October 2016 . 27609430 . 10.1016/j.cjca.2016.07.591 . free .
  123. Web site: National Institute of Health Care and Excellence . Atrial fibrillation: management . 18 June 2014 .
  124. Morin DP, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, Estes NA . The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment . Mayo Clinic Proceedings . 91 . 12 . 1778–1810 . December 2016 . 27825618 . 10.1016/j.mayocp.2016.08.022 . free .
  125. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS . European Heart Journal . 37 . 38 . 2893–2962 . October 2016 . 27567408 . 10.1093/eurheartj/ehw210 . free . Review .
  126. Ciervo CA, Granger CB, Schaller FA . Stroke prevention in patients with atrial fibrillation: disease burden and unmet medical needs . The Journal of the American Osteopathic Association . 112 . 9 Suppl 2 . eS2–eS8 . September 2012 . 23014814 . Review . https://web.archive.org/web/20160305114229/http://jaoa.org/content/112/9_suppl_2/es2.long . 5 March 2016 .
  127. Web site: FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm . FDA . 4 November 2011 . live . https://web.archive.org/web/20111105134730/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm . 5 November 2011 .
  128. Web site: 8 January 2015 . FDA approves anti-clotting drug Savaysa . FDA . 23 June 2016 . live . https://web.archive.org/web/20160619050410/https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm429523.htm . 19 June 2016 .
  129. Web site: FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation . FDA . 30 December 2012 . live . https://web.archive.org/web/20121231040217/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm . 31 December 2012 .
  130. Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, Borre ED, Raitz G, Goode A, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski AS, Sanders GD . Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review . Annals of Internal Medicine . 169 . 11 . 774–787 . December 2018 . 30383133 . 6825839 . 10.7326/M18-1523 .
  131. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ . Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy . Chest . 126 . 3 Suppl . 429S–456S . September 2004 . 15383480 . 10.1378/chest.126.3_suppl.429S .
  132. Hu A, Niu J, Winkelmayer WC . Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation . Seminars in Nephrology . 38 . 6 . 618–628 . November 2018 . 30413255 . 6233322 . 10.1016/j.semnephrol.2018.08.006 .
  133. Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP . Oral Anticoagulation in Patients With Liver Disease . Journal of the American College of Cardiology . 71 . 19 . 2162–2175 . May 2018 . 29747837 . 10.1016/j.jacc.2018.03.023 . free .
  134. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E . Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups . Thrombosis . 2013 . 640723 . 2013 . 24455237 . 3885278 . 10.1155/2013/640723 . free .
  135. Kundu A, Sardar P, Chatterjee S, Aronow WS, Owan T, Ryan JJ . Minimizing the Risk of Bleeding with NOACs in the Elderly . Drugs & Aging . 33 . 7 . 491–500 . July 2016 . 27174293 . 10.1007/s40266-016-0376-z . 3832073 .
  136. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M . Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis . Circulation . 132 . 3 . 194–204 . July 2015 . 25995317 . 4765082 . 10.1161/CIRCULATIONAHA.114.013267 .
  137. Book: Carroll JD, Webb JG . Structural Heart Disease Interventions . 2012 . Lippincott Williams & Wilkins . 978-1-4511-5396-5 . PT379 .
  138. Bennaghmouch N, de Veer AJ, Bode K, Mahmoodi BK, Dewilde WJ, Lip GY, Brueckmann M, Kleine E, Ten Berg JM . Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials . Circulation . 137 . 11 . 1117–1129 . March 2018 . 29101289 . 10.1161/CIRCULATIONAHA.117.028513 . 24988387 . free .
  139. Veeger NJ, Piersma-Wichers M, Hillege HL, Crijns HJ, van der Meer J . Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease . Journal of Thrombosis and Haemostasis . 4 . 7 . 1625–1627 . July 2006 . 16839366 . 10.1111/j.1538-7836.2006.01997.x . free .
  140. Elling T, Hak E, Bos JH, Tichelaar VY, Veeger NJ, Meijer K . Effect of Previous INR Control during VKA Therapy on Subsequent DOAC Adherence and Persistence, in Patients Switched from VKA to DOAC . Thrombosis and Haemostasis . October 2023 . 37673103 . 10.1055/a-2168-9378 . free . 11259495 .
  141. Adelakun AR, Turgeon RD, De Vera MA, McGrail K, Loewen PS . Oral anticoagulant switching in patients with atrial fibrillation: a scoping review . BMJ Open . 13 . 4 . e071907 . April 2023 . 37185198 . 10151984 . 10.1136/bmjopen-2023-071907 .
  142. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD . Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review . Annals of Internal Medicine . 160 . 11 . 760–773 . June 2014 . 24887617 . 10.7326/M13-1467 . free .
  143. Frankel G, Kamrul R, Kosar L, Jensen B . Rate versus rhythm control in atrial fibrillation . Canadian Family Physician . 59 . 2 . 161–168 . February 2013 . 23418244 . 3576947 .
  144. Thrall G, Lane D, Carroll D, Lip GY . Quality of life in patients with atrial fibrillation: a systematic review . The American Journal of Medicine . 119 . 5 . 448.e1–448.19 . May 2006 . 16651058 . 10.1016/j.amjmed.2005.10.057 . free .
  145. Trulock KM, Narayan SM, Piccini JP . Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation . Journal of the American College of Cardiology . 64 . 7 . 710–721 . August 2014 . 25125304 . 10.1016/j.jacc.2014.06.1169 . Multiple studies have compared pharmacological rate and rhythm strategies but have failed to identify a superior therapy, a finding that extends to patients with HF. ... Antiarrhythmic drug therapy is indicated as first-line therapy for AF that remains symptomatic despite adequate rate control. . free .
  146. Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I . Meta-analysis of magnesium therapy for the acute management of rapid atrial fibrillation . The American Journal of Cardiology . 99 . 12 . 1726–1732 . June 2007 . 17560883 . 10.1016/j.amjcard.2007.01.057 .
  147. Badheka AO, Shah N, Grover PM, Patel NJ, Chothani A, Mehta K, Singh V, Deshmukh A, Savani GT, Rathod A, Panaich SS, Patel N, Arora S, Bhalara V, Coffey JO, Mitrani RD, Halperin JL, Viles-Gonzalez JF . Outcomes in atrial fibrillation patients with and without left ventricular hypertrophy when treated with a lenient rate-control or rhythm-control strategy . The American Journal of Cardiology . 113 . 7 . 1159–1165 . April 2014 . 24507168 . 10.1016/j.amjcard.2013.12.021 .
  148. Book: Atrial fibrillation: national clinical guideline for management in primary and secondary care . National Collaborating Centre for Chronic Conditions . Royal College of Physicians . London . 2006 . http://www.nice.org.uk/nicemedia/pdf/cg036fullguideline.pdf . 9 May 2009 . 22 May 2013 . https://web.archive.org/web/20130522153648/http://www.nice.org.uk/nicemedia/pdf/cg036fullguideline.pdf .
  149. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL, Wann S . Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Journal of the American College of Cardiology . 61 . 18 . 1935–1944 . May 2013 . 23558044 . 10.1016/j.jacc.2013.02.001 . free .
  150. Kirkland S, Stiell I, AlShawabkeh T, Campbell S, Dickinson G, Rowe BH . The efficacy of pad placement for electrical cardioversion of atrial fibrillation/flutter: a systematic review . Academic Emergency Medicine . 21 . 7 . 717–726 . July 2014 . 25117151 . 10.1111/acem.12407 . 36859521 . free .
  151. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter . The New England Journal of Medicine . 357 . 10 . 987–999 . September 2007 . 17804843 . 10.1056/NEJMoa054686 . free . 9264507 . 11566/54713 .
  152. Watson T, Shantsila E, Lip GY . Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited . Lancet . 373 . 9658 . 155–166 . January 2009 . 19135613 . 10.1016/S0140-6736(09)60040-4 . 35178625 .
  153. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J . Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins . The New England Journal of Medicine . 339 . 10 . 659–666 . September 1998 . 9725923 . 10.1056/NEJM199809033391003 . free .
  154. Leong-Sit P, Zado E, Callans DJ, Garcia F, Lin D, Dixit S, Bala R, Riley MP, Hutchinson MD, Cooper J, Gerstenfeld EP, Marchlinski FE . Efficacy and risk of atrial fibrillation ablation before 45 years of age . Circulation: Arrhythmia and Electrophysiology . 3 . 5 . 452–457 . October 2010 . 20858861 . 10.1161/circep.110.938860 . free .
  155. Upadhyay GA, Alenghat FJ . Catheter Ablation for Atrial Fibrillation in 2019 . JAMA . 322 . 7 . 686–687 . August 2019 . 31429886 . 10.1001/jama.2019.10929 . 201099189 .
  156. Vrachatis D, Deftereos S, Kekeris V, Tsoukala S, Giannopoulos G . Catheter Ablation for Atrial Fibrillation in Systolic Heart Failure Patients: Stone by Stone, a CASTLE . Arrhythmia & Electrophysiology Review . 7 . 4 . 265–272 . December 2018 . 30588315 . 6304798 . 10.15420/aer.2018.41.2 .
  157. Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, Ramoul K, Komatsu Y, Roten L, Jadidi A, Linton N, Pedersen M, Daly M, O'Neill M, Knecht S, Weerasooriya R, Rostock T, Manninger M, Cochet H, Shah AJ, Yeim S, Denis A, Derval N, Hocini M, Sacher F, Haissaguerre M, Jais P . Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint . Circulation: Arrhythmia and Electrophysiology . 8 . 1 . 18–24 . February 2015 . 25528745 . 10.1161/CIRCEP.114.001943 . free .
  158. Han HC, Ha FJ, Sanders P, Spencer R, Teh AW, O'Donnell D, Farouque O, Lim HS . Atrioesophageal Fistula: Clinical Presentation, Procedural Characteristics, Diagnostic Investigations, and Treatment Outcomes . Circulation: Arrhythmia and Electrophysiology . 10 . 11 . e005579 . November 2017 . 29109075 . 10.1161/CIRCEP.117.005579 . 20081569 . free .
  159. Matos CD, Hoyos C, Osorio J . Pulsed Field Ablation of Atrial Fibrillation: A Comprehensive Review . Reviews in Cardiovascular Medicine . 24 . 11 . 337 . 2023 . 10.31083/j.rcm2411337 . 11272841 . 39076426 .
  160. Larson J, Merchant FM, Westerman S . Outcomes of convergent atrial fibrillation ablation with continuous rhythm monitoring . . 31 . 6 . 1270-1276 . 2020 . 10.1111/jce.14454 . 32219901 .
  161. DeLurgio DB, Gill JS, Halkos ME . Hybrid Convergent Procedure for the Treatment of Persistent and Long-standing Persistent Atrial Fibrillation . Arrhythmia & Electrophysiology Review . 10 . 3 . 198-204 . 2021 . 10.15420/aer.2021.24 . 8576514 . 34777825 .
  162. Northwestern Surgery for Atrial Fibrillation. Atrial Fibrillation Surgery
  163. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, Malaisrie SC . Concomitant atrial fibrillation surgery for people undergoing cardiac surgery . The Cochrane Database of Systematic Reviews . 2016 . 8 . CD011814 . August 2016 . 27551927 . 5046840 . 10.1002/14651858.CD011814.pub2 . Cochrane Heart Group .
  164. Blackstone EH, Chang HL, Rajeswaran J, Parides MK, Ishwaran H, Li L, Ehrlinger J, Gelijns AC, Moskowitz AJ, Argenziano M, DeRose JJ, Couderc JP, Balda D, Dagenais F, Mack MJ, Ailawadi G, Smith PK, Acker MA, O'Gara PT, Gillinov AM . Biatrial maze procedure versus pulmonary vein isolation for atrial fibrillation during mitral valve surgery: New analytical approaches and end points . The Journal of Thoracic and Cardiovascular Surgery . 157 . 1 . 234–243.e9 . January 2019 . 30557941 . 6486838 . 10.1016/j.jtcvs.2018.06.093 . 56176611 .
  165. Sef D, Trkulja V, Raja SG, Hooper J, Turina MI . Comparing mid-term outcomes of Cox-Maze procedure and pulmonary vein isolation for atrial fibrillation after concomitant mitral valve surgery: A systematic review . Journal of Cardiac Surgery . 37 . 11 . 3801–3810 . November 2022 . 36040710 . 9804989 . 10.1111/jocs.16888 . 251932594 .
  166. Zhou X, Zhang W, Lv W, Zhou Q, Li Y, Zhang L, Lu Y, Zhang J, Xing Q, Wang H, Tang B . Left atrial appendage occlusion in atrial fibrillation for stroke prevention: A systemic review . International Journal of Cardiology . 203 . 55–59 . January 2016 . 26492310 . 10.1016/j.ijcard.2015.10.011 .
  167. Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GY, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B . EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update . EuroIntervention . 15 . 13 . 1133–1180 . January 2020 . 31474583 . 10.4244/EIJY19M08_01 . 201717267 . free .
  168. AlTurki A, Huynh T, Essebag V . Left atrial appendage isolation in atrial fibrillation catheter ablation: A meta-analysis . Journal of Arrhythmia . 34 . 5 . 478-484 . 2018. 10.1002/joa3.12095 . 6174377 . 30327692 .
  169. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society . Circulation . 130 . 23 . e199–e267 . December 2014 . 24682347 . 4676081 . 10.1161/CIR.0000000000000041 .
    • Executive summary: January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society . Circulation . 130 . 23 . 2071–2104 . December 2014 . 24682348 . 10.1161/CIR.0000000000000040 . free .
  170. Kaleda VI, McCormack DJ, Shipolini AR . Does posterior pericardiotomy reduce the incidence of atrial fibrillation after coronary artery bypass grafting surgery? . Interactive Cardiovascular and Thoracic Surgery . 14 . 4 . 384–389 . April 2012 . 22235005 . 3309809 . 10.1093/icvts/ivr099 .
  171. Wijesurendra RS, Casadei B . Mechanisms of atrial fibrillation . Heart . 105 . 24 . 1860–1867 . December 2019 . 31444267 . 10.1136/heartjnl-2018-314267 . 201631227 .
  172. Blum S, Aeschbacher S, Meyre P, Zwimpfer L, Reichlin T, Beer JH, Ammann P, Auricchio A, Kobza R, Erne P, Moschovitis G, Di Valentino M, Shah D, Schläpfer J, Henz S, Meyer-Zürn C, Roten L, Schwenkglenks M, Sticherling C, Kühne M, Osswald S, Conen D . Incidence and Predictors of Atrial Fibrillation Progression . Journal of the American Heart Association . 8 . 20 . e012554 . October 2019 . 31590581 . 6818023 . 10.1161/JAHA.119.012554 .
  173. Calkins H, Hindricks G, Yamane T . 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation . . 20 . 1 . e1-e160 . 2018 . 10.1093/europace/eux274 . 5834122 . 29016840 .
  174. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA . Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis . BMJ . 354 . i4482 . September 2016 . 27599725 . 10.1136/bmj.i4482 . 7881115 . free .
  175. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA . Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies . BMJ . 532 . h7013 . January 2016 . 26786546 . 5482349 . 10.1136/bmj.h7013 .
  176. Rivard L, Khairy P . Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation . The Canadian Journal of Cardiology . 33 . 12 . 1556–1564 . December 2017 . 29173598 . 10.1016/j.cjca.2017.09.024 . Review . free .
  177. Atrial fibrillation and risk of stroke: a nationwide cohort study. Christine Benn Christiansen, Thomas A. Gerds, Jonas Bjerring Olesen, Søren Lund Kristensen, Morten Lamberts, Gregory Y.H. Lip, Gunnar H. Gislason, Lars Køber, Christian Torp-Pedersen. EP Europace, Volume 18, Issue 11, November 2016, Pages 1689–1697, https://doi.org/10.1093/europace/euv401 https://academic.oup.com/europace/article/18/11/1689/2437498 accessed 12 Oct 2020
  178. Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation. ComparativeEffectiveness Review No. 123. AHRQ Publication No. 13-EHC113-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013. www.effectivehealthcare.ahrq.gov/ reports/final.cfm.
  179. Aulin . Julia . Sjölin . Karl . Lindbäck . Johan . Benz . Alexander P. . Eikelboom . John W. . Hijazi . Ziad . Kultima . Kim . Oldgren . Jonas . Wallentin . Lars . Burman . Joachim . on behalf of the ACTIVE A and AVERROES Investigators . 2024-07-24 . Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation . Circulation . en . 10.1161/CIRCULATIONAHA.124.069440 . 0009-7322.
  180. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY . The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study . Thrombosis and Haemostasis . 107 . 6 . 1172–1179 . June 2012 . 22473219 . 10.1160/th12-03-0175 . 10318035 .
  181. Blackshear JL, Odell JA . Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation . The Annals of Thoracic Surgery . 61 . 2 . 755–759 . February 1996 . 8572814 . 10.1016/0003-4975(95)00887-X . free .
  182. Al-Saady NM, Obel OA, Camm AJ . Left atrial appendage: structure, function, and role in thromboembolism . Heart . 82 . 5 . 547–554 . November 1999 . 10525506 . 1760793 . 10.1136/hrt.82.5.547 .
  183. Sjölin K, Aulin J, Wallentin L, Eriksson N, Held C, Kultima K, Oldgren J, Burman J . Serum Neurofilament Light Chain in Patients With Atrial Fibrillation . Journal of the American Heart Association . 11 . 14 . e025910 . July 2022 . 35861814 . 9707825 . 10.1161/JAHA.122.025910 . free .
  184. Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GY . Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week . Journal of the American College of Cardiology . 73 . 5 . 612–619 . February 2019 . 30732716 . 10.1016/j.jacc.2018.10.077 . free .
  185. Madhavan M, Graff-Radford J, Piccini JP, Gersh BJ . Cognitive dysfunction in atrial fibrillation . Nature Reviews. Cardiology . 15 . 12 . 744–756 . December 2018 . 30275499 . 10.1038/s41569-018-0075-z . 52901769 .
  186. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS . European Heart Journal . 37 . 38 . 2893–2962 . October 2016 . 27567408 . 10.1093/eurheartj/ehw210 . free .
  187. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB . Rising rates of hospital admissions for atrial fibrillation . Epidemiology . 14 . 6 . 666–672 . November 2003 . 14569181 . 10.1097/01.ede.0000091649.26364.c0 . 19079630 . free .
  188. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ . Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis . Stroke . 45 . 2 . 520–526 . February 2014 . 24385275 . 10.1161/STROKEAHA.113.003433 . free .
  189. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, Weyman AE . Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study . Circulation . 82 . 3 . 792–797 . September 1990 . 2144217 . 10.1161/01.CIR.82.3.792 . free .
  190. Gourraud JB, Khairy P, Abadir S, Tadros R, Cadrin-Tourigny J, Macle L, Dyrda K, Mondesert B, Dubuc M, Guerra PG, Thibault B, Roy D, Talajic M, Rivard L . Atrial fibrillation in young patients . Expert Review of Cardiovascular Therapy . 16 . 7 . 489–500 . July 2018 . 29912584 . 10.1080/14779072.2018.1490644 . 49305621 .
  191. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE . Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study . JAMA . 285 . 18 . 2370–2375 . May 2001 . 11343485 . 10.1001/jama.285.18.2370 . free . primary source .
  192. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D . 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study . Lancet . 386 . 9989 . 154–162 . July 2015 . 25960110 . 4553037 . 10.1016/S0140-6736(14)61774-8 .
  193. Dewland TA, Olgin JE, Vittinghoff E, Marcus GM . Incident atrial fibrillation among Asians, Hispanics, blacks, and whites . Circulation . 128 . 23 . 2470–2477 . December 2013 . 24103419 . 10.1161/CIRCULATIONAHA.113.002449 . free .
  194. Vulpian A . 1874 . Note sur les effets de la faradisation directe des ventricules du coeur chez le chien . Archives de Physiologie Normale et Pathologique . 6 . 975 .
  195. McMichael J . History of atrial fibrillation 1628-1819 Harvey - de Senac - Laënnec . British Heart Journal . 48 . 3 . 193–197 . September 1982 . 7049202 . 481228 . 10.1136/hrt.48.3.193 .
  196. Nothnagel H . 1876 . Ueber arythmische Herzthatigkeit . Deutsches Archiv für Klinische Medizin . 17 . 190–220 .
  197. Mackenzie J . Observations on the Inception of the Rhythm of the Heart by the Ventricle: As the cause of Continuous Irregularity of the Heart . British Medical Journal . 1 . 2253 . 529–536 . March 1904 . 20761393 . 2353402 . 10.1136/bmj.1.2253.529 .
  198. Einthoven W . 1906 . Le telecardiogramme . Archives Internationales de Physiologie . 4 . 132–64 .
  199. Rothberger CJ, Winterberg H . 1909 . Vorhofflimmern und Arhythmia perpetua . Wiener Klinische Wochenschrift . 22 . 839–44 .
  200. Lewis T . Report CXIX. Auricular fibrillation: a common clinical condition . British Medical Journal . 2 . 2552 . 1528 . November 1909 . 20764769 . 2321318 . 10.1136/bmj.2.2552.1528 .
  201. Flegel KM . From delirium cordis to atrial fibrillation: historical development of a disease concept . Annals of Internal Medicine . 122 . 11 . 867–873 . June 1995 . 7741373 . 10.7326/0003-4819-122-11-199506010-00010 . 10629315 .
  202. Pariaut R . Atrial Fibrillation: Current Therapies . The Veterinary Clinics of North America. Small Animal Practice . 47 . 5 . 977–988 . September 2017 . 28645513 . 10.1016/j.cvsm.2017.04.002 .
  203. van Loon G . Cardiac Arrhythmias in Horses . The Veterinary Clinics of North America. Equine Practice . 35 . 1 . 85–102 . April 2019 . 30871832 . 10.1016/j.cveq.2018.12.004 . 78092141 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Atrial fibrillation".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.